Investigating the Antidepressant Mechanism of 1 mg/kg Ketamine in Rats by Higgins, Luke J M
                          
This electronic thesis or dissertation has been
downloaded from Explore Bristol Research,
http://research-information.bristol.ac.uk
Author:
Higgins, Luke J M
Title:
Investigating the Antidepressant Mechanism of 1 mg/kg Ketamine in Rats
General rights
Access to the thesis is subject to the Creative Commons Attribution - NonCommercial-No Derivatives 4.0 International Public License.   A
copy of this may be found at https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode  This license sets out your rights and the
restrictions that apply to your access to the thesis so it is important you read this before proceeding.
Take down policy
Some pages of this thesis may have been removed for copyright restrictions prior to having it been deposited in Explore Bristol Research.
However, if you have discovered material within the thesis that you consider to be unlawful e.g. breaches of copyright (either yours or that of
a third party) or any other law, including but not limited to those relating to patent, trademark, confidentiality, data protection, obscenity,
defamation, libel, then please contact collections-metadata@bristol.ac.uk and include the following information in your message:
•	Your contact details
•	Bibliographic details for the item, including a URL
•	An outline nature of the complaint
Your claim will be investigated and, where appropriate, the item in question will be removed from public view as soon as possible.
Investigating the Antidepressant 
















A dissertation submitted to the University of Bristol in accordance with the requirements for 








Unlike conventional antidepressive treatments ketamine exerts antidepressant (AD) efficacy 
within hours of administration. This rapid AD action is caused by a distinct pharmacological 
mechanism to conventional ADs and has renewed hope in a field with a once stagnant 
research effort. However, this effect is accompanied by psychotomimetic side effects, thus 
prompting the search for similar more tolerable ADs. To this end, animal research using 
rodents has been applied to understand the basic science behind ketamine’s antidepressant 
mechanism.  
Ketamine’s AD effect manifests at low subanaesthetic doses, normally applied as a 0.5 mg/kg 
infusion in humans. In rodent research, doses of 10 – 25 mg/kg are predominantly applied on 
non-translational behavioural assays. With emerging evidence of an AD effect in rats at 1 
mg/kg, we argue that the 10 – 25 mg/kg dose range is not optimally suited to investigate 
ketamine’s AD mechanism in rodents, as increased non-AD side effects will result.  
This work aimed to explore the influence of 1 mg/kg ketamine in rats and differentiate this from 
the 10 – 25 mg/kg dose range commonly applied in the literature, as well as compare this to 
the effects of ketamine’s non-AD structural analogue PCP. Here, neural activation was 
assessed with immunohistochemistry whilst the object in place task was used to examine 
differences in memory impairment, a known side effect of ketamine. From this, we found 
evidence of differentiation between 1 mg/kg and 10 – 25 mg/kg ketamine. A novel rat 
behaviour assay using flavour preference was also explored, which could be applied to future 
AD research efforts.  
Overall, whilst further work with larger n numbers is required, we propose that ketamine’s AD 
efficacy lies with an excitatory “sweet spot”, whereby ketamine’s AD action is facilitated by a 
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Depression is a prevalent psychiatric illness characterised by depressed mood, psychomotor 
impairment, sleeping disturbances and cognitive symptoms including indecisiveness and an 
inability to concentrate (Lux and Kendler, 2010). The disease affects 16% of the world 
population (Kessler et al., 2003), and with limited treatment options the disease poses a 
severe strain on society.  
Difficulties in treating depression arise from two main reasons. Firstly, its manifestation is more 
variable than is suggested by the Diagnostic and Statistical Manual of Mental Disorders IV 
(DSM-IV) criteria (commonly used to diagnose the disease), as the symptoms experienced 
between depressed patients can vary greatly, leading to subtypes (Schneck, 2009) with 
possibly distinct causes. Secondly, depression is prone to co-occur with other conditions, such 
as anxiety (Hirschfeld, 2001). This makes the condition more challenging to diagnose. Distinct 
possible subtypes, along with a complex and unknown aetiology has made the search for new 
treatments difficult and mostly unsuccessful. 
1.1.1 Aetiology of depression 
 
For decades, researchers have attempted to characterise the depressed brain in order to 
understand the root of the disease. However, there is no single unifying theory behind 
depression’s manifestation. To understand the disorders complex neurobiology, we have often 
relied on neuroimaging and post-mortem studies. These have provided some insight into the 
structures involved although the underlying cause has remained elusive. Furthermore, 
imaging data and post-mortem studies should be interpreted with caution as findings may 
result from the disease and not represent its cause. 
The prefrontal cortex (PFC) and hippocampus are regions implicated in the disease’s cognitive 
manifestation from observations of reduced volumes detected from magnetic resonance 
imaging (MRI) and post mortem studies (Sheline, 2003). Additionally, neuroimaging studies 
have consistently reported increased activity in the amygdala, a region critical for emotional 
response and memory, in depressed patients (Drevets, 2001). Considering its role in 
emotional perception it has been suggested that amygdala overactivity can lead to negative 
perception to emotionally standard stimuli (Drevets, 2001). Indeed, stimulation of the 
amygdala can evoke emotional responses (Gloor et al., 1982). With reciprocal connections 
between the PFC and amygdala, it’s proposed that the regulation of negative emotional 
responses from the PFC of the amygdala is implicated in depression. Supporting the role of 
these circuits in depression, there is evidence of PFC based attenuation of fear responses 
resulting from modulation of the amygdala (Drevets, 2001).  
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Reward and motivation are also impacted in depression. Regions responsible include the 
nucleus accumbens (NAc) and ventral tegmental area (VTA), forming part of the mesolimbic 
system. Serving as a principle reward centre, the mesolimbic systems dopaminergic afferent 
neurons extend from the VTA towards the medial prefrontal cortex (mPFC) and amygdala, 
targets which have been shown to have depleted grey matter and glial cells in the depressed 
brain (Drevets, 2001). These circuits primarily rely on dopaminergic signalling, which has been 
suggested to be altered by tricyclic antidepressants (TCA) and monoamine oxidase inhibitors 
(MAOI) resulting in their effectiveness against atypical depression (Dunlop and Nemeroff, 
2007). 
The midbrain/brainstem nuclei possess large numbers of monoaminergic neurons, that is, 
serotonergic, noradrenergic and dopaminergic projections. These are involved in a range of 
functions including mood regulation. One of the principle origins of 5-ht projections in the brain, 
the raphe nuclei, has been suggested to modulate PFC transmission involved in depression 
due to the phenotype observed in a mouse gene knockout model (Albert, Vahid-Ansari and 
Luckhart, 2014). Additionally, serotonergic nuclei including the medial and dorsal raphe nuclei 
have heavy connections to the lateral habenula, a region of recent interest in the field of 
depression (Tchenio, Valentinova and Mameli, 2016). It is in fact the serotonergic system that 
the aetiology of depression was first attributed to (Delgado, 2000). 
Whilst this research has pointed towards regions affected, the underlying cause of these 
disruptions is not understood. Of course, dysfunctional neurochemistry has been the subject 
of heavy investigation, with the first theories of the disease being based on monoaminergic 
depletion leading to disrupted synaptic function. Additionally, other neurotransmitters including 
the excitatory neurotransmitter glutamate, which targets the N-methyl-D-aspartate receptor 
(NMDAR), and the inhibitory transmitter gamma-aminobutyric acid (GABA) have been 
implicated.  Evidence of reduced PFC GABA and glutamate in depressed patients (Hasler et 
al., 2007) supports this.  
However, our understanding of how glutamatergic dysfunction and its correction could 
cause/treat depression is not understood. Evidence of increased expression of NR2A (an 
NMDAR subunit) in the amygdala post mortem (Karolewicz et al., 2009) could represent 
increased signalling of the region, leading to increased emotionally negative responses. 
Alternatively, magnetic resonance imaging has demonstrated reduced glutamate 
concentrations in the depressed brain (Mirza et al., 2004). Interestingly, this has been shown 
to be reversed by ECT (Zhang et al., 2013), a rapid antidepressant treatment, thus supporting 
glutamate as a causative factor of the disease. However, this does not address how 
monoaminergic antidepressants (ADs) relieve depression if depression is a glutamatergic 
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disease. It is possible that monoaminergic based antidepressants function by indirectly 
modulating the glutamatergic system. However, as glutamate is involved in almost every brain 
function targeting this system difficult.  
Table 1. Summary of the possible aetiology of depression. 
 
Theory Mechanism Evidence Disputes 
Monoamine theory 
of depression. 
Reduced level of 
monoamines including 5-





levels have AD efficacy. 
Delayed onset of 
therapeutic effects 
despite acute increase in 
monoamines. 
Chronic stress and 
the HPA. 
Increased stress results 
in neurodegeneration. 
Chronic stress can lead 
to neural atrophy in brain 
areas involved in mood 
regulation (Ghosal, Hare 
and Duman, 2017). 
Not everyone that is 
stressed is depressed. 
Neuropsychological Disrupted processing of 
emotionally valenced 
information results in 
depressed mood. 
Evidence of these 
cognitive bias in 
depressed patients and 
their amelioration with 
AD treatments (Harmer 
et al. 2009) 
There is no conclusive 
biological mechanism 









Genes linked to 
depression through 
genome wide association 
studies (Howard et al., 
2019). 
Carriers of risk genes 
will not necessarily 
develop depression. 
 
Chronic stress, a response used to model depression in rodents (Willner, 2017), has been 
attributed a causative factor for the depressed brain. With evidence of reduced cortical 
volumes in depressed patients (Bremner et al., 2002), chronic stress has been associated with 
dendritic remodelling (Sanacora, Treccani and Popoli, 2012) and has been suggested to 
increase susceptibility to depressive symptoms (Gould, Zarate and Thompson, 2018). 
Interestingly, glucocorticoids influence glutamate neurotransmission by increasing glutamate 
levels, potentially causing excitotoxicity and neural atrophy (Sanacora, Treccani and Popoli, 
2012) (Table 1).  
In line with this, dysfunction between the hippocampus and hypothalamic-pituitary-adrenal 
axis has been associated with depressive episodes and the reduction of cortical volumes 
(Sheline, 2003). The Hypothalamic-Pituitary-Adrenal axis (HPA) is a primary system to 
regulate stress, where the paraventricular nucleus releases corticotrophin releasing factor, 
causing release of adrenocorticotophin thus causing cortisol release from the adrenal cortex. 
Whilst being a normal physiological response, prolonged activity can lead to the death of 
hippocampal neurons (Nestler et al., 2002). However, whether stress is a definite cause of 
depression is in dispute. In fact, 50% of depressed patients do not exhibit elevated cortisol 
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(Nestler et al., 2002) demonstrating that stress is not a universal cause of depression and is 
unlikely to elicit this effect alone. Thus, chronic stress is more likely a risk factor for the disease 
and not a definitive cause. 
Therefore, varying susceptibility to environmental stressors will contribute to an individual’s 
predisposition to depression which implies a role for genetics. For example, decreased 
expression of synaptic proteins such as SYN1 have been found in depressed patients (Kang 
et al., 2012) which could contribute to increased susceptibility to stress induced 
neurodegeneration. Therefore, depression is likely a result of an interaction between the 
patient’s genetic makeup and environment. However, the genetics of depression are complex, 
with 269 genes having been associated with depression (Howard et al., 2019).  
Evidently, the root cause of depression is complex, and its theories convoluted. The so far 
misunderstood interaction between the root cause of the disease and the environment has 
presented numerous hurdles to research efforts made to understand the disease. How to treat 
such a heterogenous disorder with an undetermined cause is the great challenge of psychiatric 
research, one which has previously been answered through serendipity. Despite this, one of 
the only ways to understand depression remains with the characterisation of antidepressant 
pharmacological mechanisms. 
1.1.2 Current theories of depressions neurobiology 
 
One of the first theories of depression was the monoamine hypothesis which developed from 
the discovery that clinically effective compounds (now known as the TCAs and MAOIs) 
possessed efficacy in major depressive disorder (MDD) and shared the characteristic of 
increasing synaptic monoamines (Racagni and Popoli, 2008). Originally, iproniazid, a 
treatment for tuberculosis was found to exert antidepressant effects through its ability to inhibit 
monoamine oxidase, the enzyme responsible for the breakdown of monoamines (Elhwuegi, 
2004) leading to the idea that reduced monoamine levels caused depression. Similarly, 
characterisation of the pharmacology of the TCAs revealed they blocked reuptake of 5-HT and 
NA. Subsequently, more selective compounds were developed with reduced side effects and 
toxicity (Elhwuegi, 2004). This includes the selective serotonin reuptake inhibitors (SSRIs) 
such as paroxetine and fluoxetine, and autoreceptor antagonists such as mirtazapine 
(Elhwuegi, 2004). This long succession of antidepressant compounds which treat depression 
through their ability to increase synaptic monoamines supports the idea that depression results 




Whilst appealing in its simplicity, inconsistencies have challenged this theory. This includes 
the inability of drugs such as cocaine or amphetamine, which increase monoaminergic activity, 
to induce antidepressant effects, although the drugs short half-life may also be responsible 
due to the transience in monoamine increase. Additionally, monoamine levels increase within 
hours after treatment of conventional antidepressants but are only effective after 2-4 weeks of 
treatment (Baldessarini, 1989). In attempt to address this irregularity, modifications of the 
monoamine hypothesis have been made. For example, the delay in therapeutic response has 
been attributed to an indirect mechanism of action. It is therefore posited that monoaminergic 
ADs do not directly remediate the symptoms of depression through increased monoamines, 
but rather they activate an ensuing signalling cascade resulting in adaptive changes.  
One such hypothesis proposes that the delayed antidepressant effect of monoaminergic 
based antidepressants lies with the eventual desensitization of autoreceptors. These normally 
provide inhibitory feedback loops which temporarily prevent lasting monoamine increase. For 
example, the 5-HT1a receptor is responsible for an inhibitory feedback loop which reduces 
serotonergic neuronal activity (Gardier et al., 1996). Thus, upon initial SSRI treatment, 
synaptic levels of 5-ht are elevated however subsequent stimulation of presynaptic 5-HT1a 
autoreceptors causes membrane hyperpolarisation therefore reducing serotonergic neuron 
firing. It is only upon chronic treatment that this negative feedback loop is diminished due to 
5-HT1a desensitisation. This allows 5-HT levels to rise resulting in AD efficacy (Celada et al., 
2004). This mechanism has also been proposed for noradrenergic focused ADs, such as 
mirtazapine, which leads to desensitisation of the α2 adrenergic autoreceptor (Cottingham and 
Wang, 2012). 
Alternatively, delayed antidepressant action has been attributed to the wait required for 
neurotrophic changes to develop, including synaptogenesis, as proposed by the neurotrophic 
hypothesis of depression. Evidence of neural atrophy in depressed patients such as reduced 
PFC and hippocampal volumes, reduced size of pyramidal neurons along with decreased 
GABAergic interneurons coupled with loss of glia, has led to the postulate that depression is 
a neurodegenerative disease (Duman and Li, 2012). With these events being synonymous to 
that of chronic stress induced atrophy, the neurotrophic hypothesis of depression posits the 
disease results from the degeneration of neurons due to insufficient trophic support from 
growth factors such as brain derived neurotrophic factor (BDNF) in regions responsible for 
mood regulation, and that this is reversed after antidepressant treatment (Duman and 
Monteggia, 2006).  
BDNF is a widely expressed, small dimeric signalling protein essential for neuronal health, 
growth and survival. Its main action resides in activation of the TrkB receptor, ultimately 
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promoting neuron growth through increased gene expression and protein translation. This is 
achieved through binding to the TrkB receptor, resulting in its dimerization and tyrosine residue 
autophosphorylation. Subsequent effector molecule docking stimulates the PLCγ, PI3K and 
ERK cascades activating the CREB transcription factor and the mammalian target of 
rapamycin (mTOR) protein leading to increased gene expression and protein translation, 
respectively (Cunha, Brambilla and Thomas, 2010) (Figure 1). An immature form of the 
protein, BDNF-p75NTR also effects cellular processes through the JNK and NF-kB signalling 
pathways (Cunha, Brambilla and Thomas, 2010). 
 
Figure 1. The mature BDNF (mBDNF) and proBDNF signalling pathways.  Taken from 
Cunha, Brambilla and Thomas, 2010. 
 
Findings of decreased BDNF in the PFC, amygdala and hippocampus in depressed patients 
in conjunction with elevated BDNF following chronic conventional AD therapy (SSRI’s and 
noradrenaline selective reuptake inhibitors) (Duman and Monteggia, 2006) lends support to 
this hypothesis. Further corroboration for this originates from preclinical evidence of 
conventional antidepressant influence over the BDNF signalling pathway. For example, 
amytriptaline has been shown to increase ERK phosphorylation in rats (Galeotti and 
Ghelardini, 2012) and treatments such as sertraline, desipramine and tranylcypromine to 
inhibit stress induced BNDF downregulation in rats (Nibuya, Morinobu and Duman, 1995). 
Thus, it is proposed that increased 5-ht results in BDNF release subsequently leading to 
synaptogenesis and AD efficacy. Correspondingly, only chronic administration of 
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monoaminergic based antidepressants increases BNDF (Balu et al., 2008), temporally 
consistent with the manifestation of remission. 
1.1.3 The cognitive theory of depression 
 
Whilst providing an explanation for AD efficacy, the aforementioned theories cannot fully 
account for the remission of depressive symptoms. To explain the manifestation of 
antidepressant efficacy, the drugs psychological action must be addressed. One theory, 
known as the cognitive theory of depression, proposes that depression results from disrupted 
cognitive processes (Beck, 1963). This relates to depressed patients having depressive 
thought processes consisting of illogical self-criticism and a strong tendency to negatively warp 
reality. Therefore, the cognitive theory of depression posits that depression results from biased 
perception of information, distorting the depressed patients interpretation of external stimuli 
and internal thoughts (Beck, 2005).  
This can occur at memory retrieval, demonstrated by the tendency to remember negative 
words over positive, and can result in negative self-rumination (Harmer, Goodwin and Cowen, 
2009). New and present information will also be affected and has been demonstrated in 
depressed patients where negative biases are observed during interpretation of neutral stimuli 
(Harmer et al., 2009). These behaviours are not observed in healthy individuals. Thus, it is 
plausible that the amelioration of these negative cognitive bias is a necessity for AD efficacy, 
as proposed by the neuropsychological hypothesis of AD action (Harmer, Goodwin and 
Cowen, 2009).  
Supporting the role of cognitive bias for AD action, these behaviours are ameliorated with 
conventional AD treatment. Interestingly, unlike their antidepressant efficacy, monoaminergic 
AD treatments attenuate negative bias with acute treatment. For example, Harmer et al., 2003 
observed how a single dose of reboxetine, duloxetine and citalopram increased recognition of 
happy facial expressions in healthy individuals. Additionally, Murphy et al., 2009 found that a 
single dose of citalopram reduced activity of the amygdala in response to fearful faces. 
Therefore, conventional antidepressants have effects on emotional processing before the 
manifestation of their antidepressant effects, suggesting that the two are separate, albeit 
connected, effects. 
Therefore, it is hypothesized that the delay in conventional antidepressant treatment results 
from these drugs not directly altering mood, but rather ameliorating these negative biases thus 
allowing the depressed patient to interpret events in positive way. This allows the patient to 
relearn positive, emotional experience. It is thus proposed that the relearning of positive 
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behaviour is the root of the delayed AD effect of antidepressant, despite attenuating negative 
biases hours after treatment (Harmer et al., 2009).  
1.2 Rapid acting antidepressants 
 
Rapid acting antidepressants, which show AD efficacy within hours, show great improvement 
over conventional treatments and have posed major challenges to the receptor adaption and 
neurotrophic hypotheses of depression. Primary candidates include ketamine, now licensed 
by the Food and Drug Administration (FDA) as esketamine, and scopolamine. Scopolamine, 
an anticholinergic agent, has demonstrated rapid antidepressant effects lasting for 3 to 4 days 
post administration of the first infusion (Furey and Drevets, 2006). Whilst its precise 
mechanism is unknown its AD efficacy likely lies with the drugs inhibitory action on the 
cholinergic system. This is supported by the pro-depressive action of pharmacologically 
increased cholinergic activity in depressed individuals (Drevets, Zarate and Furey, 2013). 
Ketamine, on the other hand, has shed interest into the glutamatergic system. Ketamine is a 
non-competitive antagonist at the NMDAR, but also shows affinity for the D2 and sigma 
receptors. Similar to scopolamine, ketamine acts within hours (Figure 2) even in treatment 
resistant patients who do not respond to first line antidepressant drugs (Aleksandrova, Phillips 
and Wang, 2017).  
Whilst the specific receptor targeted by scopolamine is unknown, it’s thought that its selectivity 
for the M3 receptor subtype (30 times more than that of amitriptyline) may be vital for its AD 
action, as is suggested by its dose dependent effect (Furey and Drevets, 2006). Furthermore, 
it has been argued that muscarinic acetylcholine (mACh) receptor antagonism contributes to 
the AD action of TCAs, with amitriptyline being the most effective whilst displaying the highest 
mACh affinity thus supporting the role of mACh receptor in the AD action of scopolamine 
(Furey and Drevets, 2006).  
Interestingly, this dose dependent characteristic is shared by ketamine, which is only known 
to exert AD activity at subanaesthetic doses, also potentially due to selective receptor subtype 
targeting. This could include receptors containing the GluN2B subunit, which has been 
associated with glutamatergic AD action (Miller et al., 2014), or increasingly activated 
NMDARs which become more susceptible due to ketamine’s use dependent mechanism. 
Furthermore, both drugs have demonstrated the requirement of BDNF signalling for eliciting 
an AD effect in rodents (Autry et al., 2011; Ghosal et al., 2018). Therefore, these rapid acting 
treatments possess similarities in their neurobiological mechanisms, although whether these 




Figure 2. First evidence of ketamine’s antidepressant effect in humans. Ketamine’s 
antidepressant effect manifests within hours, characterised by reduction in the Hamilton 
Depression Rating Scale (HDRS) which does not temporally synchronize with its psychoactive 
properties or effect on cognition, as shown by the and Visual Analog Scales (VAS) and Brief 
Psychiatric Rating Scale (BPRS), respectfully. Data represents mean changes of scores, error 
bars represent SEM, * = p<0.05, ** = p<0.01 and *** = p<0.001 when compared against 
groups. # = p<0.05, ## = p<0.01 and ### = p<0.001 when compared to baseline. Graph taken 
from Berman et al., 2000.  
 
Whilst promising, caution is required due to side effects and the unknown mechanism behind 
the rapid AD effect. Further, the long-term effects of these treatments have received little 
investigation despite the brief temporary nature of its antidepressant effect which lasts 1 week 
(Furey and Drevets, 2006; Newport et al., 2015). Additionally, both treatments pose a real 
threat of memory loss as a side effect. Indeed, ketamine’s main pharmacological action is 
NMDAR antagonism, a receptor central to Long Term Potentiation (LTP) posited to underlie 
learning and memory (Izquierdo et al., 2008), whilst anticholinergic drugs have been known to 
facilitate cognitive decline (Papenberg et al., 2017). However, there is evidence of six 
ketamine infusions actually improving cognitive performance (Zheng et al., 2019), thus the 
true side effect of subanaesthetic ketamine remains to be determined. 
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Also, ketamine’s psychotomimetic influence also poses a risk of abuse (Schatzberg, 2014), a 
threat demonstrated by the drugs popularity in the rave culture. Further, the hallucinatory 
properties of ketamine have been used to model schizophrenia (Farber, 2003) which aptly 
demonstrates the potential of distressing episodes, especially as robust screening methods 
used in clinical research (Murrough et al., 2013) may not be employed in the clinic.  
However, ketamine and scopolamine are not the only rapid acting antidepressants. 
Psychedelic drugs such psilocybin and ayahuasca have also demonstrated rapid 
antidepressant qualities. Although, research on these drugs has been challenging due to 
being listed as schedule 1 drugs. However, they have demonstrated interesting AD qualities. 
Ayahuasca is a mixture of two plants, Psychotria viridis and Banisteriopsis caapi, which 
possesses N, N-dimethyltryptamine (N,N-DMT) (Carbonaro and Gatch, 2016) and MAOI’s 
such as harmine (Riba et al., 2003). In a randomized placebo controlled trial, treatment 
resistant patients of depression experienced significant improvement in both HDRS and 
Montgomery–Åsberg Depression Rating Scale (MADRS) scores, an effect which manifested 
within one day and was maintained 7 days after receiving the ayahuasca treatment, containing 
0.36 mg/kg of N,N-DMT (Palhano-Fontes et al., 2019) which is believed to be the active 
compound in the treatment. Whilst an interesting finding, the rich mixture of compounds in 
ayahuasca makes it difficult to assert a mechanism behind its action. 
Psilocybin, the active compound in magic mushrooms has also demonstrated a rapid 
antidepressant effect AD measured by the Quick Inventory of Depressive Symptomatology 
(QIDS) at 1 week (Carhart-Harris et al., 2017). Interestingly, this effect may be due to 
psilocybin’s influence on cognitive bias, evidenced by psilocybin’s ability to reduce depressed 
patients sensitivity to negative emotion faces (Kometer et al., 2012). Additionally, psilocybin 
possesses a mood elevating effect (Nicholas et al., 2018) which has been associated with 
altered connectivity in the default mode network (Carhart-Harris et al., 2017), although 










1.2.1 Ketamine, a proof of concept 
 
As mentioned, ketamine’s main action is as an NMDAR receptor antagonist. The NMDAR is 
a tetrameric ligand gated ion channel which binds with its endogenous agonist glutamate and 
co-agonist glycine (Figure 3). Thus, the NMDAR belongs to the glutamatergic system, the 
primary excitatory drive of the brain. Being entirely distinct from the primary mechanism of 
current treatments, the NMDAR and glutamatergic system have been a focus of research to 
elucidate ketamine’s rapid relief of depression for a novel source of AD treatments. Back 
translational research has largely supported the NMDARs role in this antidepressant effect, 
such as reduction of immobility in the widely used forced swim test (FST) for depression (Autry 
et al., 2011). Furthermore, ketamine’s antidepressant efficacy is shared with another NMDAR 
antagonist and GluN2B selective compound, CP-101,606 (Newport et al., 2015). 
 
 
Figure 3. Illustration of ketamine’s binding within NMDAR ion channel pore. Taken 
from (Kemp and McKernan, 2002). For simplicity, only two subunits are highlighted. Note, 






Through NMDAR antagonism, ketamine has been proposed to influence glutamatergic 
neurotransmission which results in downstream effects leading to AD efficacy. A hallmark of 
subanaesthetic ketamine administration is increase PFC glutamate, known as the glutamate 
surge (Abdallah et al., 2018). An explanation for this effect, known as the disinhibition 
hypothesis, proposes that this results from disinhibition of tonically active inhibitory GABAergic 
interneurons extending to the PFC pyramidal neurons (Miller, Moran and Hall, 2016). This 
could then lead to synaptic plasticity which has been associated with its AD effect (Li et al., 
2010) as will be discussed below. Alternatively, a direct hypothesis proposes that ketamine 
promotes protein synthesis through directly inhibiting NMDARs which leads to a compensatory 
homeostatic increase in activity. This then results in protein synthesis supposedly responsible 
for ketamine’s AD effect (Miller, Moran and Hall, 2016). 
Both these hypotheses require the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
receptor (AMPAR). The AMPAR is required for synapse formation and maintenance 
(McKinney, 2010), and is thus postulated to be essential for both the aforementioned direct 
and indirect hypotheses of ketamine (Miller, Moran and Hall, 2016). Indeed, the AMPAR 
receptor is widely present with the NMDAR, and is normally essential for the NMDARs activity 
due to removal of its magnesium block. Therefore, the AMPAR is highly likely to be required 
for an NMDAR mediated AD effect. In fact, some propose that the AD effect of ketamine solely 
lies with the AMPAR (Inta et al., 2016).   
A notion which has received attention is that it is not ketamine itself but its metabolite, 
hydroxynorketamine (HNK), which exerts therapeutic action (Zanos et al., 2016) independent 
of NMDAR blockade whilst requiring AMPAR activation. However, whether the AMPAR can 
mediate AD efficacy independent of the NMDAR is in dispute. Further, Collingridge et al., 2017 
argue that the enantiomer of the metabolite to which Zanos et al., 2016 attribute the 
antidepressant influence of to 2R, 6R-HNK, could not of been produced from the S-enatiomer 
of ketamine which has been shown to exert potent AD effects (Singh et al., 2016; Daly et al., 
2018). Furthermore, evidence of AD effects of GluN2B selective NMDAR antagonists 
(Preskorn et al., 2008; Miller et al., 2014) supports NMDAR involvement. Additionally, AMPAR 
receptors are often required for NMDAR activation as they facilitate removal of the NMDARs 
Mg2+ block through membrane depolarisation (Bliss and Collingridge, 1993). Thus, 
ameliorating ketamine’s AD effect through AMPAR antagonism does not prove an NMDAR 
independent effect. 
It is important to consider that ketamine is widely administered as its racemic mixture, 
consisting of R-ketamine and S-ketamine which exists as a 1:1 mix. The posited implications 
this has for the NMDAR hypothesis is that contrasting reports have been made against the 
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antidepressant efficacy of each enantiomer (Zanos et al., 2016; Collingridge et al., 2017). 
Indeed, some posit that R-ketamine, which is 2 to 4 times less potent than esketamine at the 
NMDAR (Domino, 2010) is the more antidepressant compound such as in preclinical animal 
models (Zhang, Li and Hashimoto, 2014; Yang et al., 2015). This would suggest that the 
NMDAR is not the principal mediator of ketamine’s AD effect. In contrast, others believe that 
esketamine, which has shown promise over ketamine’s racemic mixture (Singh et al., 2016), 
is the more effective treatment. However, a direct comparison between the enantiomers at the 
same dose has not been made, although evidence of different fMRI response patterns (Masaki 
et al., 2019) supports this investigation.  
The fact that other NMDAR antagonists such as MK-801 lack AD influence (Newport et al., 
2015) has questioned what is behind ketamine’s AD effect. This has triggered an important 
search to discern the characteristic of what makes ketamine AD compared to similar non-AD 
NMDAR antagonists such as MK-801 or AP-5. It is possible that ketamine’s unique 
pharmacokinetic/pharmacodynamic profile may be responsible for its AD action against other 
NMDAR antagonists. For example, its short half-life and intermediary NMDAR binding affinity 
between memantine and MK-801 could facilitate AD action. On the other hand, ketamine’s 
action on the opioid system, has been suggested to be responsible for its AD effect, as 
coadministration with the opioid system antagonist naltrexone has been shown to attenuate 
ketamine’s AD effect (Williams et al., 2018). 
Despite some uncertainty, NMDAR antagonism remains a viable means of ketamine’s 
antidepressant action. Furthermore, ketamine differs from its non-AD relatives such as MK-
801 in NMDAR affinity and pharmacokinetic profile. The question of why some NMDAR 
receptor antagonists display antidepressant influence, whilst others do not, remains 
unanswered. Indeed, being able to differentiate these would undoubtedly contribute towards 
our understanding of ketamine’s mechanism of action.  
1.3 NMDAR antagonism and antidepressant action  
1.3.1 Unselective NMDAR antagonists 
 
Ketamine’s binding site is found deep within the NMDAR channel (Figure 3) where it occludes 
the channel pore upon opening thus preventing ion flow. Furthermore, ketamine displays 
virtually no selectivity towards subtypes of the NMDAR (Zorumski, Izumi and Mennerick, 
2016). This makes ketamine a use dependent, uncompetitive and unselective NMDAR 
antagonist, a mechanism shared by the similar antagonist’s phencyclidine (PCP) and MK-801. 
However, these compounds dissociate much more slowly from the NMDAR than ketamine 
(Zorumski, Izumi and Mennerick, 2016), resulting in slower on/off kinetics and increasing drug 
induced channel opening, resulting in higher potency. Due to this, they cause more intense 
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psychotomimetic effects, as is well known for the once popular drug of abuse PCP, also known 
as ‘angel dust’. Consequently, these drugs have not been tested in human clinical trials for 
treating depression. Whilst being shown to be effective in rodent models of depression, such 
as the FST, MK-801 has differed from ketamine in that is does not last 24 hour after initial 
treatment in mice (Autry et al., 2011; Yang et al., 2016; Zanos et al., 2016). PCP on the other 
hand has not been investigated as extensively as an antidepressant in human or animal 
assays, but has been shown to reduce immobility in the mouse FST (Solati, Ahmadi and 
Salari, 2011). However, due to the FST’s lack of translational validity, this is not a reliable 
indicator of AD efficacy.  
Due to their similar pharmacology, any differentiation made between ketamine and its 
analogues could provide clues to ketamine’s AD mechanism. For example, memantine, a drug 
used to treat dementia and other neurological disorders such as Parkinson’s disease (Johnson 
and Kotermanski, 2006) has been investigated as an antidepressant. Despite possessing the 
desirable qualities of sharing similarities with ketamine’s mechanism of action and being 
clinically well tolerated (Gideons, Kavalali and Monteggia, 2014), memantine has failed to 
show antidepressant efficacy in humans (Zarate et al., 2006b). Whilst binding to a similar site 
as ketamine, memantine exerts a weaker block of the NMDAR due to its low trapping effect, 
resulting from lower NMDAR affinity (Mealing et al., 1999). This is likely the cause of its low 
psychotomimetic influence and potentially explains its lack of antidepressant action. This could 
suggest that a certain degree of NMDAR inhibition is required for AD response. However, this 
remains uncertain, although a connection between ketamine’s dissociative influence and AD 
effect has been made (Luckenbaugh et al., 2014). Furthermore, its lack of effect on rodent 
models of depression have been attributed to its lack of effect on NMDARs at rest due to the 
influence of magnesium ions (Gideons, Kavalali and Monteggia, 2014).  
1.3.2 GluN2B 
 
The NMDAR is a tetrameric receptor, made up of two GluN1 and two GluN2 subunits (Figure 
3). The GluN1 subunit binds glycine, whilst the GluN2 subunit binds glutamate and exists as 
four subtypes consisting of GluN2A, GluN2B, GluN2C and GluN2D. Some NMDAR 
antagonists such as CP-101,606 confer a selective preference over GluN2B containing 
receptors. CP-101,606 binds to a distinct region to that of ketamine, consisting of a cleft 
between the GluN1 and GluN2B ATD domains (Burger et al., 2012). Despite this alternative 
mode of action, CP-101,606 has demonstrated antidepressant efficacy at both human trials 
(Preskorn et al., 2008)  and rodent models (Poleszak et al., 2016). Though note that only one 
CP-101,606 trial has taken place and did not show as robust as an effect as ketamine 
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(Preskorn et al., 2008). Despite little research, the ability of the GluN2B antagonist to induce 
antidepressant action could be used to dissect ketamine’s mechanism. 
A second GluN2B selective NMDAR antagonist, MK-0657, displayed hints of an 
antidepressant effect through oral administration, although this did not reach significance. 
However only 5 patients completed the study as the manufacturer discontinued the drugs 
production (Ibrahim et al., 2012). Thus, whilst showing some promise, further investigation is 
required for GlunN2B selective antagonists to be employed in the clinic. 
How the GluN2B containing NMDAR is involved in antidepressant efficacy is still in debate. 
One hypothesis is that inhibition of GluN2B NMDARs leads to the promotion of neurotrophic 
signalling as their activation has been shown to suppress mTOR protein synthesis (Miller et 
al., 2014). However, this does not explain how a non-selective antagonist such as ketamine 
could achieve antidepressant efficacy which required GluN2B selectivity. In attempt to address 
this, it has been proposed that GluN2B receptors are predominantly located extrasynaptically, 
and are tonically activated by ambient glutamate thus increasing susceptibility to ketamine’s 
open channel block (Miller et al., 2014; Miller, Moran and Hall, 2016). However, the 
extrasynaptic location of GluN2B NMDARs is in dispute. 
1.3.3 Other ways of targeting the NMDAR  
 
To open, the NMDAR requires both the removal of the Mg2+ block via depolarisation and the 
binding of glutamate and its co-agonist glycine (Figure 3), which binds to a distinct site at the 
GluN1 subunit (Johnson and Ascher, 1987). It has therefore been attempted to use this as an 
opportunity for the development of another strategy to target the NMDAR to exert 
antidepressant effect. An example is D-cycloserine, a treatment for tuberculosis which has 
affinity for the glycine site at the NMDAR. 
To date two trials have been conducted, one using a lower dose of 250 mg/day which did not 
improve depressive symptoms (Heresco-Levy et al., 2006), whilst a second study using a 
higher dose of 1000 mg/day significantly improved HDRS scores (Heresco-Levy et al., 2013). 
This suggests a dose dependent effect. Being a partial agonist D-cycloserine will begin to 
exert NMDAR antagonism only at higher concentrations, which corresponds with the results 
gained from the two aforementioned studies. However, these were preliminary studies with an 
n number of 22 (Heresco-Levy et al., 2006) and 26 (Heresco-Levy et al., 2013) and D-
cycloserine was used as an adjunct therapy in each study, with patients already being on 
certified antidepressant treatments. Therefore, further investigation is required. A further 
attempt at developing an NMDAR co-agonist antidepressant has been attempted with GLXY-
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13 also known as rapastinel, however its antidepressant efficacy has not been established 
(Newport et al., 2015). 
A potential use for D-cycloserine is as an adjunct therapy with ketamine has also been 
investigated. Here, Kantrowitz et al., 2015 found that D-cylcoserine administration after an 
initial ketamine infusion caused a significant overall response over an 8-week period. 
However, this study was not blinded or placebo controlled as well as having a small sample 
size of 12. Therefore, further investigation is needed, particularly on the AD effect of D-
cycloserine independent from other AD treatments. 
1.4 Ketamine, a unique case 
 
Whilst many attempts at replicating ketamine’s AD action have been undertaken, none have 
achieved consistent efficacy (Newport et al., 2015). This raises the question of what it is that 
gives ketamine this reliable therapeutic effect. A possibility is ketamine’s rich pharmacology, 
which extends to the dopaminergic, serotonergic and opioid transmitter systems (Newport et 
al., 2015). Particularly, ketamine’s activity at the sigma receptor has been postulated to 
contribute to its antidepressant effect (Robson et al., 2012). However, ketamine’s affinity for 
the receptors behind its secondary actions are low and would likely require high doses to 
cause an effect which does not correspond to the low dose 0.5 mg/kg infusions at which it’s 
antidepressant action manifests.  
Alternatively, it could be specific properties which ketamine possesses at the NMDAR. This 
could be exemplified by memantine’s inability to relieve depression (Zarate et al., 2006b; 
Zarate et al., 2013), which could be due to differential actions at the NMDAR such as influence 
of receptor desensitisation (Glasgow et al., 2017) or memantines inability to block resting 
NMDAR currents in the presence of magnesium (Gideons, Kavalali and Monteggia, 2014). To 
further investigate, more comparisons between ketamine and similar antagonists such as PCP 
would benefit this search. 
1.4.1 Dose dependent effect of ketamine 
 
To achieve its AD effect ketamine must be administered in subanaesthetic doses. Typically, 
0.5 mg/kg of ketamine is given as a single infusion across 40 minutes (Newport et al., 2015; 
Zorumski, Izumi and Mennerick, 2016) which is associated with mild dissociative side effects 
rated by the Brief Psychiatric Rating Scale and Clinician Clinician-Administered Dissociation 
State Scales (Berman et al., 2000).  
In rats, a clear difference, both behaviourally and neurochemically exists between anaesthetic 
doses of ketamine (>80 mg/kg) and subanaesthetic doses (<30 mg/kg). Firstly, whilst doses 
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of 10 & 5 mg/kg have been shown to increased phosphorylated levels of mTOR, 4E-BP1 and 
p70S6K indicating synaptic strengthening, 80 mg/kg does not (Li et al., 2010). Secondly, 3, 
10 and 30 mg/kg ketamine increase both glutamate cycling and glucose metabolism in rat 
mPFC whilst 80 mg/kg does not (Chowdhury et al., 2017). These differences provide evidence 
of distinct dose dependent biochemical effects in rodents.  
Due to this the preclinical literature has focused on subanaesthetic doses ranging between 10 
– 25 mg/kg when investigating ketamine’s AD efficacy. However, evidence that 1 mg/kg 
ketamine modifies affective bias in rats (Stuart et al., 2015) suggests that studying ketamine’s 
AD effect at doses of 10 mg/kg may still be high enough cause secondary non-AD effects. In 
support, doses of 5 mg/kg and 4 mg/kg have been shown to impair responses to pre-pulse 
inhibition and have locomotor influence (Imre et al., 2006; Radford et al., 2017). Therefore, 
the behavioural aspect of the preclinical ketamine story could be fundamentally flawed as 
despite application of subanaesthetic doses within the 5 – 10 mg/kg range, which can still 
promote neurotrophic effects, may still be causing non-AD effects. Thus, the effects viewed at 
the behaviour level, particularly that of the FST, could be non-specific to ketamine’s 
antidepressant action. 
Logically, an effect more specific to the lower dose ranges could be due to ketamine preferably 
targeting a subpopulation of NMDA receptors. In support, a similar dose dependence may be 
seen with CP-101,606. As discussed, CP-101,606 has also been shown to display AD effects 
whilst maintaining dissociative effects. Indeed, dissociative effects have been observed from 
higher doses of CP-101,606 by Preskorn et al., 2008, who reduced the dose from 0.75 mg/kg 
per hour for 1.5 hours, followed by 0.15 mg/kg 6.5 hours to 0.5 mg/kg per hour for 1.5 hours 
due to moderate/severe psychotomimetic effects. The more dissociative influence of the 
higher dose corresponds with the different pharmacological magnetic resonance imaging 
profiles between 15 mg/kg and 5 mg/kg CP-101,606 in rats observed by Tang et al., 2018. 
They discovered that whilst a 5 mg/kg dose produced region specific activation at the mPFC 
and ventral orbital cortex and anterior cingulate cortex, 15 mg/kg resulted in more universal 
activity at the cortical/sub-cortical regions, an effect shared by 3 mg/kg ketamine. This 
discrepancy could suggest that even 3 mg/kg ketamine is high enough to exert nonspecific 
effects, increasing its dissociative influence.  
Another issue with higher doses of ketamine is its effect on cognitive processes and memory. 
Indeed, 3 mg/kg ketamine can disrupt spatial memory in rats (Pitsikas, Boultadakis and 
Sakellaridis, 2008). Thus, doses within the 10 – 25 mg/kg range often used in the preclinical 
literature likely cause cognitive disturbances. This is exemplified by studies showing 8 mg/kg 
effects memory acquisition (Pallarés et al., 1995), and the study by Dix et al., 2010 
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demonstrating that 10 mg/kg ketamine consistently impaired performance in a cognitive 
battery test indicating reduced learning, memory and cognitive flexibility. However, as the 0.5 
mg/kg infusion used in humans has also been linked to dissociative effects (Newport et al., 
2015), temporary cognitive impairments do not necessarily mean a lack of AD response. 
Furthermore, with evidence arguing against the AD efficacy of doses of 0.1 and 0.2 mg/kg 
ketamine (Fava et al., 2018), the dissociative side effects of 0.5 mg/kg may be inseparable 
from ketamine’s AD effect. Whether this is due to side effects from the necessary dosage, or 
a result of the same causative factor, remains to be determined. 
Indeed, the neurobiology behind the AD action of subanaesthetic doses is not fully understood, 
although it likely results from the need of subtler neurocircuitry influences which anaesthetic 
doses cannot exert. This suggests that for antidepressant effects to manifest, a large 
proportion of NMDARs will remain unblocked (Zorumski, Izumi and Mennerick, 2016) 
facilitating subsequent recruitment for eliciting an antidepressant effect. Thus, global NMDAR 
suppression that accompanies anaesthetic doses would compromise this mechanism.  
1.5 What is ketamine’s antidepressant mechanism? 
1.5.1 Neurotrophic signalling 
 
The neurotrophic hypothesis has been used to describe ketamine’s AD mechanism which has 
been suggested to act via neurotrophic signalling pathways, namely that of the mTOR pathway 
(Figure 4) (Duman and Voleti, 2012). It has been proposed that increased exocytosis of BDNF 
resulting from a ketamine triggered glutamate surge subsequently stimulates the TrkB 
receptor and therefore the synthesis of synaptic proteins including GluA1 and PSD95 (Duman 
et al., 2012). Indeed, ketamine’s AD effect in rodents has been ameliorated in BDNF knockout 
animals (Autry et al., 2011), and by an infusion of a BDNF antibody (Lepack et al., 2014). 
Additionally, intraperitoneal (i.p.) administration of the L-type calcium channel antagonist 
verapamil and nifedipine has been shown to inhibit ketamine’s effect on immobility in the FST 
(Lepack et al., 2014). Further downstream effectors have also been implicated, including 





Figure 4. Signalling pathways attributed to ketamine’s antidepressant mechanism in 
the neurotrophic hypothesis of depression. Disinhibition of GABAergic interneurons 
through ketamine NMDAR antagonism leads to increased synaptic glutamate. This in turn 
activates AMPAR facilitating calcium entry via voltage gated calcium channels (VDCC) which 
triggers BDNF exocytosis. Subsequently, the TrkB pathway is activated leading to increased 
expression of synaptic proteins thus promoting neurogenesis. Diagram is from Duman et al., 
2012. 
 
Overall, a large proportion of preclinical research has supported this neurotrophic-based 
theory of ketamine’s AD action. However, despite its appealing simplicity it would be rash to 
accept this as ketamine’s AD action for several reasons. Firstly, understanding how 
intracellular cascades translate to the remission of depressive symptoms has been an age-
old challenge of preclinical psychiatric research and the current literature fails to make such 
extrapolation beyond the use of despair related rodent models such as the FST. Secondly, 
inconsistencies exist in the timeline between the appearance of ketamine’s therapeutic effect 
and neurogenesis. Specifically, it is unlikely that a seemingly chronic process such as dendritic 
spine remodelling could account for an AD effect which manifests within hours and fails to 
explain why ketamine’s AD action is transient. Lastly, the behavioural element to this research 
is limited in that it is based on despair-based models of depression, which are based on the 
tautology of their capability to detect monoaminergic based AD efficacy and do not replicate 
the aetiology of depression. However, despite these irregularities, this research has identified 





1.5.2 Neuropsychological model 
 
Acting within hours, ketamine’s rapid onset has made it stand out from current therapies. This 
highlights the question of what causes the difference in the onset of action of current 
treatments and ketamine. Thus, the cognitive hypothesis has been applied in attempt to 
address this inconsistency. 
As discussed, the amelioration of negative biases and subsequent effect on emotional 
relearning has been proposed to be responsible for the delayed action of conventional 
antidepressants (Harmer, Goodwin and Cowen, 2009). However, this does not correspond 
with the rapidity of ketamine’s antidepressant effect, as its rapid onset would theoretically not 
be long enough for these same learning processes to take place. One postulate is that 
ketamine ameliorates negative biases based on recollection, and not new information, 
resulting in rapid but transient effect (Stuart et al., 2015). 
A possible mechanism is that ketamine acts to normalise neural processes which in the 
depressed person is leading to these negative biases. By monitoring depressed patients’ 
brains using functional MRI (fMRI) whilst undertaking the dot probe task, which assesses 
attention and emotional processing and is used to assess cognitive bias through the 
interpretation emotional faces, Reed et al., 2018 found that post ketamine administration the 
depressed group’s activity at the right frontal cortex, dorsal anterior cingulate cortex (dACC), 
and left anterior gyrus was decreased to match that of placebo. Murrough et al., 2015 
demonstrated that ketamine reverses differences in striatal connectivity found in MDD patients 
compared to that of healthy controls using emotion perception tasks and fMRI. Furthermore, 
Abdallah et al., 2017b, using resting state functional connectivity fMRI demonstrated that 
ketamine normalised reduced connectivity within the PFC in depressed patients.  
Therefore, ketamine’s ability to reverse these functional abnormalities in the depressed brain 
may result in its ameliorating effect on negative bias and thus AD effect. Indeed, evidence of 
the normalisation of altered brain activity in depressed patients in response to conventional 
ADs (Delaveau et al., 2011) supports the possibility that new rapid acting ADs such as 
ketamine exert a similar normalising effect, albeit through different mechanisms. 
1.5.3 Neurocircuitry 
 
Three major neural networks including the default mode network (DMN) responsible for self-
rumination, the central executive network (CEN) associated with cognitive function and the 
salience network (SN) which is involved in emotional regulation (Mulders et al., 2015), have 
received noteworthy attention in the field. The DMN, centred around the medial prefrontal 
(anterior DMN) and anterior cingulate (posterior DMN) cortices has increased within network 
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connectivity at rest in depressed patients compared to healthy controls (Mulders et al., 2015). 
This could potentially lead to maladaptive self-rumination. Other associations include altered 
connectivity between the SN and DMN, such as hypoconnectivity with the nucleus accumbens 
and increased connectivity with the amygdala, posited to influence emotional cognition (Kaiser 
et al., 2015). Thus, ascertaining whether these depressive traits are reversed with ketamine 
is of prime interest due to the potential insight into its mechanism this could offer.  
In an attempt to address this, extensive imaging studies have applied fMRI to investigate the 
depressed patient’s brain to identify the networks responsible for the diseases affective and 
cognitive manifestation. A recent focus has resided on resting state functional connectivity 
(RSFC), which provides an insight into the brain which is not actively engaged in a task. This 
allows the search for key networks disrupted in the depressed brain at rest. 
Ketamine has been shown to decrease functional connectivity between key regions such as 
the dorsal nexus, medial prefrontal cortex and pregenual anterior cingulate (Scheidegger et 
al., 2012) suggesting ketamine’s antidepressant effect lies with decreasing functional 
connectivity with the DMN. However, this study was undertaken in healthy controls and is not 
directly applicable to the depressed patient. Furthermore, a separate study by Mueller et al. 
2018 failed to find a significant influence of subanaesthetic ketamine on the DMN, however 
increased connectivity between the ECN and anterior cingulum and frontal gyrus, along with 
decreased connectivity between the ECN and SN seeds were found.  
Whilst these findings could suggest a mode of action for ketamine’s antidepressant influence 
these are preliminary notions due to the inconsistency of findings. This is a common problem 
in the neuroimaging field due to the different methods of analysis used and the large number 
of heterogenous circuits studied. Furthermore, it is difficult to definitively separate ketamine’s 
dissociative side effects from its therapeutic AD influence based solely on imaging data, and 
as Mueller et al., 2018 propose, ketamine’s reduction of ECN connectivity with SN regions 
including the occipital load could represent ketamine’s dissociative effects. To resolve this, 
ketamine’s pharmacodynamics should be compared with that of similar drugs to evaluate 
whether these effects can be isolated. However, in order to uncover ketamine’s antidepressant 
mechanism, we cannot rely on biochemical observations or imaging data as it is impossible to 
determine how these will translate.  
However, despite these difficulties this approach can elucidate on the neurocircuit dynamics 
involved in the cognitive aspects of the disorder which cannot currently be resolved at the 
molecular level. Furthermore, this area of research provides a link between ketamine’s 
neuropharmacodynamics and the behavioural manifestation of its antidepressant effect. 
Indeed, altered connectivity within relevant circuits provides an additional platform for 
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understanding how functional changes in the brain present as symptoms of depression and 
its remission resulting from acute ketamine treatment. This includes those such as negative 
cognitive biases, which cannot be solely gained from in vitro research. Therefore, we must 
expand on these observations with novel methods of behavioural psychopharmacology using 
sophisticated animal research techniques. 
1.6 Animal research and depression 
 
Animal research has provided a vital method for the investigation of psychiatric illness and the 
means to understand the basic science behind these diseases. Using these approaches, the 
neurobiology of depression and discovery of therapeutic compounds has been aided greatly. 
Indeed, it was through animal research that the antidepressant properties of NMDAR 
antagonists were first encountered (Trullas and Skolnick, 1990), facilitating the discovery of 
ketamine’s antidepressant activity.  
Considering the difficulties of modelling higher cognitive functions in rodents, investigating 
depression using animal research is challenging and often resorts to stress induced states. 
Due to this, a set of behavioural tests sensitive to chronic stress have proven a popular 
screening method for antidepressant efficacy, such as the FST which relies on despair related 
behaviours. These animal assays are based on a tautology from an effect observed from 
monoaminergic antidepressants (Hendrie et al., 2013), contributing to an unsuccessful search 
for new antidepressant medicines (Berton, Hahn and Thase, 2012). With most of the literature 
relying on either despair-based animal models including the FST, learned helplessness assay 
and novelty suppressed feeding test, the behavioural aspect of the ketamine story is lacking. 
This is because these assays were not designed to elucidate a drug’s pharmacological 
mechanism, but to simply detect antidepressant effect (Nestler and Hyman, 2010). 
However, recent developments in preclinical behavioural research has led to the development 
of novel behavioural assays based on depression’s cognitive theory. The application of these 
more translational methods should enable developments of a more complete understanding 
of the mechanism of antidepressants such as ketamine. 
1.6.1 Studying cognitive and affective biases in rodents 
 
Sadness and anxiety are natural responses to negative events. However, in the case of the 
depressed individual these feelings are exacerbated and inappropriately regulated, leading to 
negative reactions to undeserving events. This stems from dysfunctional interpretation and 
regulation of information and responses, a postulate of the cognitive theory of depression first 
proposed by Beck, 1963. This theory has provided a good explanation for the remission of 
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depression and fits with evidence of cognitive bias in depressed individuals (Gotlib et al., 2004; 
Peckham, McHugh and Otto, 2010).  
The negative interpretation of ambiguous information is a serious impairment present in 
depressed patients, one which the widely used despair and hedonic based rodent models fail 
to elucidate. However, with increasing focus on cognitive bias, novel opportunities for 
preclinical behavioural studies have been presented. These include the affective bias task 
(ABT) and judgement bias task (JBT) (Hales et al., 2014). As will be discussed, these assays 
provide a novel opportunity to study the cognitive influence of psychoactive drugs such as 
ketamine, providing further insight into their cognitive mechanism than the commonly used 
despair-based assays. 
1.6.2 The judgement bias task  
 
The rat judgement bias task comprises of learning to differentiate two distinct tones, one that 
corresponds to receiving an appetitive reward after the press of a lever, whilst the second tone 
represents a less positive outcome (low reward/no reward) or punishment. Once this is learnt, 
a third ambiguous tone is played, and the choice of the rat recorded. The animal’s choice is 
then used to judge the animal’s cognitive bias. A choice for the rewarding lever would indicate 
a positive bias, whilst the anticipation of punishment suggests a negative bias (Hales et al., 
2014). Supporting this test’s validity, exposure to chronic stress results in a negative shift in 
cognitive bias, as more lever presses were made to avoid punishment (Papciak et al., 2013).  
As proposed by Harmer, Goodwin and Cowen, 2009, it is possible that the delayed action of 
current antidepressants resides with the eventual relearning of positive emotional experience 
which occurs after amelioration of negative affective biases. This temporal inconsistency has 
previously been impossible to investigate using behavioural animal research. Using the JBT, 
Hales et al. discovered differences between delayed onset and rapid onset antidepressants, 
where conventional monoaminergic treatments have no acute effect on cognitive bias whilst 
rapid acting antidepressants including ketamine, the GluN2B containing NMDAR selective 
antagonists CP-101,606 and the muscarinic antagonist scopolamine induced positive 
cognitive bias compared to vehicle baseline (Figure 5).  
Interestingly, induction of positive bias was induced by chronic administration of the 
conventional antidepressant fluoxetine (Hales, Houghton and Robinson, 2017). These 
findings resemble the subjective reporting of remission in depressed patients, which occurs 
hours after ketamine administration but weeks after conventional monoaminergic 
antidepressants. In further corroboration with human AD trials, Hales et al. demonstrated that 
NMDAR antagonists similar to ketamine such as memantine which have not been shown to 
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possess antidepressant efficacy (Newport et al., 2015), lack influence on cognitive bias in the 















Figure 5. Effect of acute pharmacological manipulation of affective state in rats 
performing in the judgment bias task. Accumulated data from Hales, Robinson and 
Houghton, 2016; Hales, Houghton and Robinson, 2017; Bartlett et al. unpublished. Data 
represent choice made in reaction to ambiguous cue, error bars represent SEM, * = p<0.05. 
 
1.6.3 The Affective Bias Task  
 
Like the JBT, the ABT is based on the cognitive neuropsychological hypothesis but differs in 
its focal point being on the influence of affective state on memory, as in how affective state at 
the time of learning leads to emotional bias, or how drugs which modify affective state effect 
biases at the time of recall (Hales et al., 2014).  
Through learning to discriminate between two distinct digging substrates to attain a reward, 
the rats can be subjected to affective state manipulations associated with one of the specific 
digging substrates. Affective state manipulations may be pharmacological, such as an 
antidepressant compound, or environmental such as social enrichment. Thus, each of the 
rewarded digging substrates is encountered under different conditions, with one of these being 
under the affective state manipulation. The digging substrates are associated with rewards on 
alternating days against a blank, and then presented together on a final choice day. The rat’s 
choice between the two reward paired substrates is then used to quantify their affective bias. 
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A ratio favouring the affective state manipulated digging substrate represents a positive bias, 
whilst a ratio favouring the unmanipulated substrate indicates a negative bias. 
Having been reliably demonstrated to exhibit similar results to those attained in human studies 
described in section 1.1.3 (Figure 6), affirming its predictive validity, the ABT offers an 
additional source of research on ketamine’s influence on cognitive biases. That is, to 
investigate ketamine’s effect on the interpretation of emotionally valanced information. 
 
Figure 6. Validation of the ABT. Accumulated data for the bowl digging ABT (Stuart et al., 
2013; Stuart, Wood and Robinson, 2017). Data displayed as % choice bias, error bars 
represent SEM, * = p<0.05, ** = p<0.01, *** = p<0.001. 
 
Application of the ABT has distinguished ketamine from conventional antidepressant 
treatments. Whereas the conventional antidepressant fluoxetine is only able to induce a 
positive bias when administered before the pairing session, ketamine has this effect only when 
administered prior the choice session (Stuart et al., 2015) (Figure 7). Stuart et al., 2015 posit 
that whilst ketamine ameliorates previously acquired negative biases at recall, conventional 
antidepressants function by attenuating negative bias at the time of processing. This identifies 
a key difference in the influence of these antidepressant drugs on affective bias, which 
possibly explains the different temporal onsets of their therapeutic effect. However, ketamine’s 
lack of effect on the processing of new information infers the drug will not work long term 
(Stuart et al., 2015). Consistent with the different onset of these treatments, the ABT has 
provided a valuable insight into the cognitive mechanisms behind the antidepressant action of 
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Figure 7. Ketamine ameliorates previously acquired negative biases. From Stuart et al., 
2015. Stuart et al. demonstrate that 1 mg/kg ketamine (KET) is able to attenuates a previously 
acquired negative bias when administered before the choice session, whilst venlafaxine (VFX) 
did not improve over vehicle (VEH). Negative biases were induced through administration of 
FG7142 (a GABA receptor inverse agonist) (A) or restraint stress (B) before substrate pairing 
sessions. Data shown as mean±SEM, n = 16. ** = p < 0.01 and ** = p<0.001 when compared 
to theoretical 0% bias. # = p<0.05 and ## = p<0.01 when compared against vehicle control. 
 
Taken together, the JBT and ABT have started to provide valuable insight into the role of 
cognitive bias in ketamine’s antidepressant action. Whilst the JBT, consistent with the 
remission of symptoms, has shown to immediately effect the rat’s judgement bias resembling 
the patients subjective reporting of remission (Hales, Houghton and Robinson, 2017), the ABT 
has shown that this effect could be achieved through attenuating negative bias at time of recall 
(Stuart et al., 2015). This demonstrates the potential this line of research offers and warrants 
its continuation. 
This is of significance because to truly understand ketamine’s AD action we need to connect 
objective behavioural parameters to basic neuroscience. Application of the ABT allows this as 
it opens way for testing specific biological manipulations on a depressive behavioural trait 
whilst providing the advantages of in vivo research. By assessing the neurobiological effect of 
an efficacious treatment in this assay such as that of 1 mg/kg ketamine (Stuart et al., 2015), 
deductions can be made as to what is behind this behavioural effect. This will allow more 
definitive research into ketamine’s AD mechanism. Therefore, the current work aims to 
validate and optimise the ABT whilst characterising the influence of 1 mg/kg ketamine. The 
latter of which will provide insight to the basic science behind 1 mg/kg ketamine’s effect in the 





1.7 Aims and objectives 
 
To investigate if an alternative approach to the ABT could provide a higher throughput and 
more reliable method to study the effects of ketamine on cognitive processes linked to MDD. 
To try to understand the regions and circuits activated by low dose ketamine and compare 
these with higher doses and non-efficacious NMDAR antagonists. 
To use the object in place version of the novel object recognition test to provide a different 




















































Whilst the FST is known to be sensitive to monoaminergic ADs its predictive validity for non-
monoaminergic ADs has been questioned (Berton, Hahn and Thase, 2012; Stuart et al., 2013). 
Preclinical studies on ketamine often use the FST as a means to detect AD efficacy (Li et al., 
2010; Autry et al., 2011; Zanos et al., 2016) however these results may be confounded by 
ketamine’s locomotor side effects. Additionally, non-AD antagonists such as MK-801 have 
also reduced immobility in the FST test (Autry et al., 2011; Zanos et al., 2016), although this 
only manifests at a 1-hour pre-treatment time this demonstrates that non antidepressant 
NMDAR antagonists can elicit a false positive in this test. 
Furthermore, the test’s primarily function is as a predictive validator and does not recreate 
depressions aetiology (Belzung and Lemoine, 2011). For this reason, the affective bias test 
provides an advantage over the sole predictive validity of the forced swim test due to its 
translational validity, as it recreates part of the depressive cognitive pattern known as affective 
bias (Stuart et al., 2013). This offers a novel approach to understand how preclinical research 
may translate to remitting behaviour in humans. 
However, despite exciting developments the ABT is highly sensitive to experimenter effects 
and requires a high level of skill in behavioural methods to successfully train animals to 
perform the task. To explore this, we undertook a repeat of the 2 vs 1 ABT and negative bias 
induction using cortisol injection undertaken by Hinchcliffe et al., 2017. Having failed to 
achieve reliable reproducibility we conducted a trial of a modified version of the assay, 
replacing the experience of digging substrate with that of flavoured solutions, where the reward 
consisted of a sucrose solution and not reward pellets. The objective was to reduce the 
opportunity for the induction of bias from the experimenter to the animals by minimizing 
experimenter-animal interaction. By reducing opportunity of the experimenter influencing the 
animal’s behaviour and therefore choice, the risk of compromising the affective bias should 
be minimized and increase the likelihood of reliable bias induction. 
The ability to use flavours for associative learning has been well characterised in rats. First 
investigation into this was undertaken by Holman, 1975, who demonstrated rats exhibit a 
preference for a flavour paired with more concentrated saccharin solution than the flavour 
paired with a less concentrated saccharin solution. Furthermore, it is possible to maintain this 
association despite the removal of the reward associated as this type of learning can avoid 
extinction with properly designed experiments (Delamater, 2004). The possibility to facilitate 
associative learning using flavours provides the opportunity to apply the same principles used 
in the bowl digging ABT.  
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Like the ABT, the flavour preference ABT applies pavlovian conditioning in order to associate 
an unconditioned stimulus, in this case sucrose solutions, with a conditioned stimulus of 
flavour to form the unconditioned response of an affective bias, manifested by a preference to 
the more highly rewarded flavour. Thus, the formation of a positive association, such as a 
preference for a more highly rewarded flavoured solution, can be used to investigate the 
influence of drugs on cognitive bias, synonymous to the bowl digging ABT. 
The design of a different experiment which aims to study affective bias in the same context 
not only offers more experimental options but will also support the test’s theoretical validity. 
To achieve this, we assessed this variation of the affective bias task using the same 
experimental structure and concepts as the bowl digging task but replacing digging substrates 
with flavoured sucrose solutions. The ability to recreate an affective bias in this varied version 





16 male lister hooded rats were used to conduct the ABT task (~500–550 g, Harlan, UK). 
Another 12 male lister hooded rats (300-350g) were then used to conduct the flavour 
preference ABT. Animals were housed in pairs and all experimental work was conducted 
within a 12:12 h light–dark cycle (lights off at 0700h), between 9 am – 5pm. Bowl digging ABT 
animals were food restricted to 100g of laboratory chow per day with ad libitum water whilst 
the flavour preference animals had ad libitum access to chow and water. All animals were 
provided with environmental enrichment (cardboard tube, plastic housing and chew block). 
Weight of the animals was monitored weekly. 
All work was approved by the UK Home Office and was conducted in adherence to the 
regulations of the 1986 Animals (Scientific Procedures) Act and EU Directive 2010/63/EU.  
2.2.2 Drug treatment 
 
Corticosterone was purchased from Sigma Aldrich (UK). Cortisol was dissolved in 5% dimethyl 
sulfoxide (DMSO) and 95% sesame oil and a dose volume of 1 ml/kg was used.  Treatments 
were administered through subcutaneous (s.c.) injection 30 minutes before pairing sessions. 
2.2.3 Affective Bias test behavioural study 
 
Apparatus: ABT experiments were carried out in a clear Perspex box arena with an area of 40 
cm2. A lining paper was laid down and replaced each day of testing. For substrate placement, 
two glazed bowls were placed at either side of the arena separated by approximately 2 inches. 
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A variety of materials were used for digging substrates, including hemp bedding, pompons, 
coconut fibres and shredded cardboard. After each ABT experiment, a fresh and new digging 
substrate combination was used. 
Training: Animals had already been trained for the ABT prior these experiments. The training 

























Table 2. Training procedure for the rat affective bias test. Adapted from Stuart et al., 
2015. 
Day 1: Arena habituation Exploration of two bowls each containing 3 food pellets. 
The rat is allowed to approach both bowls and eat all the 
pellets. 
When all pellets are eaten the rat is removed, the bowls re-
baited and the rat placed back into the arena. 
Criteria: total of 10 mins exploration. 
Day 2: Digging training 1 Exploration of two bowls each containing 1cm sawdust and 3 
food pellets (1 on surface and 2 buried). 
Each rat is allowed to dig in both bowls to find the pellets. 
When all pellets are eaten the rat is removed, the bowls re-
baited and the rat placed back into the arena. 
Criteria: completion of 12 discrete trials (max. 2 min each trial) 
Day 3: Digging training 2 Choice of two bowls each containing 2cm sawdust and 2 
buried food pellets. 
Each rat is allowed to dig in one bowl to find the pellets. The 
other bowl is removed when the rat makes a choice (ie. Digs 
in a bowl). 
Criteria: completion of 12 discrete trials (max. 30 sec each 
trial). 
Day 4: Digging training 3 Choice of two bowls each containing 2cm sawdust and 2 
buried food pellets. 
Each rat is allowed to dig in one bowl to find the pellets. The 
other bowl is removed when the rat makes a choice (ie. Digs 
in a bowl). 
Criteria: completion of 12 discrete trials (max. 30 sec each 
trial). 
Day 5: Novel substrate Exploration of two bowls containing a novel digging substrate 
(eg. Mouse bedding) and 2 buried food pellets 
Each rat is allowed to dig in one bowl to find the pellets. The 
other bowl is removed when the rat makes a choice 
Criteria: completion of 12 discrete trials (max. 30 sec each 
trial). 
 
Test protocol: Each ABT study took place over five days, consisting of four pairing days and 




Rats experienced two distinct positive associations between two digging substrates, under 
neutral or affective state manipulation. To facilitate this, two distinct substrates are paired with 
the finding of reward. The rats formed this association during pairing days. At each pairing 
day, rats encountered one of the two reward paired substrates along with a “blank” substrate, 
which never hid a reward and was kept consistent during the test (Figure 8B). The reward 
paired substrates alternated across four days. The aim is for the rat to learn that to achieve 
the reward it must dig the reward paired substrates, and not the blank substrate. The reward 
is kept consistent (1 reward pellet) for both digging substrates (unless it is the 2 vs 1 ABT, see 
below) and across the pairing sessions.  
 
 
Figure 8. Affective Bias Test procedure. (A) Timeline of a single ABT study, consisting of 
four pairing days (two for each reward paired substrate) and a final test day (choice between 
the two reward-paired substrates). Treatment options here are either before pairing session 
with one of the rewarded substrates, shown here as substrate A, or before preference testing 
on choice day. (B) Set up for ABT for pairing sessions and choice day. Random reinforcement 
on choice day is achieved through pseudorandom pellet placement, where there is a 1 in 3 
chance the rat will find the pellet. Taken from Stuart et al., 2015. 
 
After the animal had made their decision, judged by which bowl they began to dig first, the 
other bowl was removed and the latency to dig recorded. Once the animal had chosen the 
reward paired substrate six consecutive times their pairing day was complete. If an animal 
took longer than 20 seconds to decide this was counted as an omission, a maximum of twenty 
trials per animal was undertaken each pairing day.  
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The days on which the animals were paired with the affective state manipulated or control 
reward paired substrates would alternate over the four days. The position of the bowls was 
pseudorandom and counterbalanced to prevent the animals making associations based on 
direction/location and to ensure active participation of the task.  
The choice day took place on day 5 when both previously reward-paired substrates were 
presented together for the first time and the rat was required to make a choice based on its 
prior memory of the substrate reward association (A or B). In this study the animals were not 
treated on choice day. The positions were again pseudorandomised. Unlike pairing days, the 
rat would undergo 30 consecutive trials. Bias was quantified relative to the affective state 
manipulated substrate with a positive bias seen when animals made more choices for the 
treatment-paired substrate versus control and vice versa for negative bias. As all other 
conditions except affective state were kept constant, any bias could be attributed to the 
affective state manipulation. Latency to dig was also recorded with a maximum of 10 seconds, 
anything longer was recorded as an omission. Random reinforcement using reward pellets 
was used to maintain the animal’s interest in responding but limit any new learning. 
Affective state manipulations: In the case of the 2 vs 1 ABT the manipulation consisted of an 
extra reward pellet during pairing sessions (not choice day) in order to induce a positive bias 
towards that substrate. To induce a negative bias, 10 mg/kg cortisol or vehicle was 
administered through s.c. injection 30 minutes before pairing sessions. 
2.2.4 Flavour preference test 
 
Apparatus: Flavour preference experiments took place in large clear plastic cages, distinct 
from those of residence. Sipper sacks were used to hold the liquid solutions in which metal 
sipping tubes were inserted. Once solutions needed to be changed the sacks were replaced 
and sipping tubes washed in distilled water. Due to the experimental procedure explained 
below, the bags would be changed after the four-day habituation period so that the subsequent 
sucrose free solutions on choice day would not be contaminated. Sipper sacks were replaced 
between experiments to avoid flavour contamination. 
Approach 
Habituation: Animals were place in the cages for 10 minutes with the two sipper sacks in place, 
one containing 0.1% saccharin and the other 0.1% saccharin with 10% sucrose. No flavours 
were added at this stage. Sipper sack position was fully counterbalanced. Over the habituation 
period a clear preference for the 10% sucrose solution developed (Figure 9). This resulted in 
a significant interaction between 10% saccharin solution consumption and trial (Greenhouse-
Geisser corrected two-way repeated measures ANOVA, F (1.89, 20.76) = 8.67, p = 0.002). 
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Furthermore, Sidak corrected simple effects analysis statistically confirms the difference in 
consumption between the saccharin and saccharin/10% sucrose solutions appears from day 
2 (mean increase 2.833 ml, 95% CI 1.790 to 3.877, p<0.001) and is maintained and increased 
from day 3 (mean increase 4.083 ml, 95% CI 2.197 to 5.969, p = 0.001) and day 4 (mean 
increase 5.333, 95% CI 3.572 to 7.096, p<0.001). 
 
 
Figure 9. Flavour preference test habituation. Data shown as mean±SEM, n = 12. Two-
way repeated measures ANOVA, Sidak corrected simple effects analysis, * = p<0.05, ** = 
p<0.01, *** = p<0.001. 
 
Test protocol:  
To replicate the more highly rewarded substrate in the bowl digging 2 vs 1 ABT, one flavour 
was paired with a 15% sucrose solution whilst the less rewarded substrate contained 5% 
sucrose. The blank flavour was free of any sucrose. All flavours possessed 0.1% saccharin to 
maintain motivation on choice day where neither previously rewarded flavoured solutions 
included sucrose. 
The rewarded flavours (A and B) were paired with rewarding sucrose solutions on alternating 
pairing days similar to the bowl digging ABT task. Here, the rat was exposed to the rewarded 
flavour along with the “blank” solution, which only contain 0.1% saccharin. Across the 4 days 
A or B would either be paired with 5% or 15% sucrose solution depending on the individual as 
flavour and reward allocation was fully counterbalanced. On the final choice day, the rat would 
choose between A or B, but this time the solutions only contained 0.1% saccharin in order to 




Figure 10. Environment layout of the flavour preference ABT. Synonymous with the bowl 
digging ABT, the flavour preference ABT utilises left and right positions of the associative 
memory cues. Note that position of flavours was fully counterbalanced. 
 
2.2.5 Statistical analysis 
 
For the bowel digging ABT, choice bias was calculated by subtracting 50 from the percentage 
of choices made for the affective bias manipulated substrate against the total number of trials 
(30). This gave a percentage choice bias. Similarly, for the flavour preference ABT, choice 
bias was assessed by calculating the percentage of the affective state manipulated flavour 
consumed against that of the total volume consumed and a value of 50 was then subtracted. 
The experiments were assed using individual student t-tests. For the affective bias, directional 
bias and substrate bias results were tested against a theoretical mean of 0. To assess the 
number of pellets eaten results were tested against a theoretical mean of 10, to match the 1 
in 3 probability of the rats finding the pellets by chance.  
Unpaired student t-tests were also used for the flavour preference assay. During which, 







2.3.1 Affective bias induction in ABT bowl digging task 
 
The trials were assessed on an individual bases and individual t-tests were applied. A 
significant affective bias induction was only achieved during the third 2 vs 1 ABT attempt (one 
sample t-test, t(15) = 3.656, p = 0.0023, Figure 11A), which also displayed a significant 
substrate bias (one sample t-test, t(15) = 3.656, p = 0.0023, Figure 11B). A significant leftward 
bias was observed on choice day for trial 1 (one sample t-test, t(11) = 4.729, p = 0.0006) and 
trial 2 (one sample t-test, t(15) = 2.145, p = 0.0487). This was not observed in subsequent 
trials 3 & 4 (Figure 11C). The number of pellets eaten did not stray from expected value of 10 
other than during ABT trial 2 (one sample t-test, t(15) = 3.313, p = 0.0047, Figure 11D). 














































































































Figure 11. Results for the 2 vs 1 ABT.  A) Affective bias index. B) Substrate bias. C) 
Directional bias. D) Number of pellets eaten. Data shown as mean±SEM, Trial 1 n = 12, Trials 





No bias was observed after attempt to induce a negative bias through a cortisol paired 
substrate (Figure 12). Furthermore, a lack of substrate choice, directional or substrate bias 
was also recorded (Figure 12). The number of pellets eaten was not significantly different from 































































































Figure 12. Lack of influence of cortisol on the bowl digging ABT. 10 mg/kg cortisol was 
administered 30 minutes prior pairing sessions with the cortisol-paired substrate through i.p. 
injection. Data shown as mean±SEM, n=8. 
 
To review potential causes for the lack of a reliable affective bias, the trial to criterion data for 
the pairing sessions was reviewed. From this, it appears that by the second pairing session, 





























































































































Figure 13. Number of trials undertaken to reach criterion during bowl digging ABT. A) 
2 vs 1 ABT, i) trial 1, ii) trial 2, iii) trial 3, iv) trial 4. B) Cortisol ABT. Data shown as mean±SEM, 





2.3.2 Positive bias induction in the flavour preference ABT 
 
Pairing of a 15% sucrose solution with a distinct flavour resulted in the induction of a positive 
bias as measured by solution consumption (Figure 14A & B). This was significant in both 
attempts, undertaken by the author (one sample t-test, t(10) = 2.970, p = 0.0140, Figure 14A) 
and by Bartlett J (one sample t-test, t(10) = 2.948, p = 0.0146, Figure 14B). No significant 




















































































































Figure 14. 2vs1 bias in flavour preference ABT. A) Conducted by the author B) Work of J. 
Bartlett. A positive bias towards the 15% sucrose paired solution induced in both trials, free of 










2.4.1 The flavour preference ABT avoids technical difficulties encountered in 
the bowl digging ABT 
 
We successfully induced a positive bias in the flavour preference ABT using flavour preference 
for associating the unconditioned and conditioned stimulus. We suggest the cause of the 
dissimilarity between the results gained from the bowl digging ABT and flavour preference 
ABT is due to reduced experimenter-animal interaction as the flavour preference ABT does 
not provide as much opportunity for the induction of unintentional biases in the task. For 
example, the sipper sacks are positioned prior to the placement of the rats into the test cages. 
This not only makes the task faster and easier to undertake but reduces the interaction 
between the experimenter and the animal therefore minimizing the opportunity for them to 
influence each other’s behaviour and judgement. The flavour preference therefore offers an 
easier alternative to the bowl digging ABT which is more accessible to less experienced 
handlers.  
Inducing a flavour preference using sugars is a well-established method to study animal 
behaviour (Dwyer and Quirk, 2008; Touzani, Bodnar and Sclafani, 2013). However, ours is 
the first to apply this to the study of affective bias. By removing the reward (sucrose) on choice 
day, the bias observed (Figure 14A & B) likely results from the animal’s associative memory 
and is not influenced by satiety which can affect consumption (Sclafani, 2002). However, a 
reward induced bias cannot be directly compared to an affective bias, thus further tests on the 
flavour preference ABT with pharmacological affective bias manipulators are required. 
Therefore, before further assumptions are made about the flavour preferences reliability, it 
should undergo similar pharmacological test as that performed in Stuart et al., 2013 and 
Hinchcliffe et al., 2017 to determine if its predictive validity matches that of the ABT. Despite 
these drawbacks, the flavour preference test has shown promise as another method for 
investigating affective biases in rodents. This therefore offers an additional approach to study 
cognitive bias in rodents, alongside the bowl digging ABT.  
The flavour preference ABT may therefore prove an additional behavioural tool to investigate 
ketamine’s mechanism of action. As flavour preference has been suggested to involve regions 
implicated in depression such the amygdala and PFC (Malkusz et al., 2012), studying low 
subanaesthetic doses of ketamine at 1 mg/kg could consolidate the findings of ketamine’s 
effect on the PFC in Stuart et al. 2015. However, considerations must be made when using 
the flavour preference test to investigate ketamine. For example, NMDAR neurotransmission 
in the amygdala has been shown to be necessary for flavour preference acquisition (Touzani, 
Bodnar and Sclafani, 2013), consistent with the NMDARs role in LTP and learning. Thus, 
43 
 
when testing ketamine’s effect on affective bias at the time of information processing, a 
memory ameliorating effect must not be confused with attenuating affective bias.  
2.4.2 Inability to induce affective bias in the ABT likely results from practical 
difficulties 
 
As no positive bias with increased sugar pellet reward or negative bias with 10 mg/kg cortisol 
injection was induced (Figure 11 & 12) we did not replicate the results found by Hinchcliffe et 
al., 2017. Review of the pairing day data across both the 2 vs 1 and cortisol experiments 
demonstrated that by the second pairing day the animals were able to achieve 6 consecutive 
trials with some success. However, no bias was observed on choice day. This suggests that 
the animals did not use associative memory to locate the pellets on pairing days. As the 
number of pellets eaten was not consistently above that of the expected value of 10 (Figure 
11D & 12D), it is unlikely the animals used olfactory cues to locate the sugar pellets on choice 
days. 
The animals used in the study had been previously trained and run in the ABT with reliable 
results and so the failure to replicate this was most likely attributed to the experimenter. One 
of the challenges of this experiment is the judgement of what constitutes a committed dig, and 
thus choice of the rat. To those new to the task this can present an opportunity for error as it 
can be difficult to judge whether the dig is due to exploratory behaviour which precedes their 
decision or is a result of the decision itself. Incorrect judgement of the rat’s decision will 
therefore disrupt the formation of an affective bias and result in the rats using other strategies 
to locate the pellet. 
2.4.3 Conclusions 
 
Unlike the bowl digging ABT, a positive bias towards the higher value reward flavour was 
achieved using a flavour preference version of the ABT (Figure 14). This lends support to the 
notion that affective biases can be studied in rodents using this more efficient approach. 
Additionally, reduced experimenter-animal interactions decrease the risk of human induced 
error. However, as an appetitive bias is not synonymous with affective bias, this task must be 
validated with other affective state manipulations. 
Overall, the flavour preference test offers a potential supplementary experiment with which to 
study affective bias in animals. The focus should now shift towards using these tasks to gain 
more insight into the cognitive effect of ketamine and how this relates to its AD mechanism. 
For example, the cognitive influence on affective bias needs to be tested the day after, not just 
straight after injection to determine whether the influence on cognitive bias lasts as long as its 







































As discussed, Stuart et al., 2015 found a cognitive effect of ketamine at an i.p. dose of 1 mg/kg, 
an effect attributed to actions at the PFC after replication of the result by direct infusion into 
the PFC. This effective dose of 1 mg/kg is the lowest dose used in an in vivo depression study 
as most publications use doses of 10-25 mg/kg in rodents (Autry et al., 2011; Zanos et al., 
2016). As ketamine’s AD effects manifest at low subanaesthetic doses (Berman et al., 2000; 
Zarate et al., 2006a) a 1 mg/kg dose may more closely resemble the doses used in clinical 
trials due to potential motor side effects which can occur between 10-25 mg/kg in rats (Qian, 
Brown and Carlton, 1996).  
Low subanaesthetic doses of ketamine exert an excitatory influence at the PFC which has 
been associated with its AD effect (Li et al., 2016). In support, subanaesthetic doses of 
ketamine have been demonstrated to elevate cortical glutamate in both humans (Stone et al., 
2012) and rats (Kim et al., 2011), an effect that has been attributed to disinhibition of inhibitory 
GABAergic interneurons resulting in increased pyramidal activity (Homayoun and 
Moghaddam, 2007). Due to the association of PFC excitation and the AD effect of 
subanaesthetic ketamine the characterisation of the neurobiological effects of 1 mg/kg 
ketamine at the rat PFC is warranted.  
The rat prefrontal cortex is a composite of sub regions including the cingulate (CG), infralimbic 
(IL) and prelimbic (PL) regions. These regions have been directly connected to ketamine’s AD 
mechanism, as direct infusions into the rat IL cortex produce antidepressant effects also 
replicated by optogenetic stimulation (Covington et al., 2010; Fuchikami et al., 2015). 
Furthermore, the rat anterior cingulate cortex, a region involved with cognitive processes such 
as decision making (Kennerley et al., 2006) and causes pro depressant effects in the FST 
upon lesioning (Bissiere et al., 2006).  
We therefore set out to investigate how the dose of 1 mg/kg ketamine influenced regional 
activation of the rat PFC. By monitoring activation of the IL, PL, and CG regions we sought to 
identify AD associated effects, whilst also monitoring activation of the motor cortex (Mt) to 
identify non-specific motor side effects. This was compared against its relative PCP at 0.3 
mg/kg. The aim of this being to discern any differences between the two drugs, which might 
identify characteristics which give ketamine its AD properties. We also investigated a dose 
dependent influence at 1 mg/kg, 10mg/kg and 25 mg/kg to differentiate 1 mg/kg from these 
higher doses to again determine characteristics that provide 1 mg/kg ketamine’s AD effects. 
Our method of measuring neuronal activity was through analysing expression of c-fos protein, 
a product of a proto-oncogene whose expression is linked to neuronal action potentials 
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(Okuno, 2011). To investigate the role of GABAergic interneuron dishinbition in the effect of 1 
mg/kg ketamine and 0.3 mg/kg PCP, we recorded glutamate decarboxylase 67 (GAD67)/c-
fos colocalization in the PFC. GAD67 is an enzyme used to convert glutamate to GABA and 
is thus associated with the spatial location of GABAergic interneurons.  
3.2 Methods 
3.2.1 Animals and dosing methods 
 
For the experiments comparing 1 mg/kg ketamine against 0.3 mg/kg PCP, 16 male lister 
hooded rats were used (~500–550 g, Harlan, UK). Another 16 male lister hooded rats (~300-
350g, Harlan, UK) were used for the dose response experiment. 
Animals were housed in pairs and all experimental work was conducted within a 12:12 h light–
dark cycle (lights off at 0700h), between 9 am – 5pm. All animals had ad libitum access to 
laboratory chow and water and were provided with environmental enrichment (cardboard tube, 
plastic housing and chew block). Weight of the animals was monitored weekly. 
All work was approved by the UK Home Office and was conducted in adherence to the 
regulations of the 1986 Animals (Scientific Procedures) Act and EU Directive 2010/63/EU.  
3.2.2 Drug treatment 
 
Both ketamine and PCP treatments were made with sterile 0.9% saline solution using a dose 
volume of 1 ml/kg. Ketamine used was purchased from Sigma Aldrich. PCP was purchased 
from Tocris, UK. Treatments were administered through i.p. injection 90 minutes before killing. 
Animals were killed through barbiturate overdose. 
In the ketamine vs PCP experiment, 6 animals received 1 mg/kg ketamine, another 6 received 
0.3 mg/kg PCP and the final 4 received saline control. During the ketamine dose experiment 
ketamine was administered at 1 mg/kg, 10 mg/kg and 25 mg/kg along with saline control. In 
this experiment 4 animals were allocated to each treatment group. 
3.2.3 Immunohistochemistry 
 
Tissue preparation: Animals were killed 90 minutes post drug/vehicle delivery using 
intraperitoneal barbiturate overdose. Once death was confirmed through cessation of 
breathing, and lack of response to paw/ankle pinch, brains were extracted and post-fixed in 
4% paraformaldehyde (PFA) for 24 hours before being placed in 30% sucrose solution. Once 
brains had sunk in the sucrose solution the brains were cut using a freezing microtome into 
40 μm sections. Using The Rat Brain in Stereotaxic Coordinates (Paxinos & Watson, 1982), 
neural landmarks such as the forceps minor were used to identify regions of interest, to ensure 
correct collection of the prefrontal cortex. Once sections were cut, they were placed in 
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cryoprotectant and stored at -20 degrees Celsius. Cryoprotectant was composed by adding 
300g sucrose and 300ml ethylene glycol to 500ml of 0.1M phosphate buffer and making up to 
1L with distilled water. 
Immunohistochemistry protocol: The protocol used was a standard 2-day protocol with all 
steps taking place at room temperature. 
• Day 1: Once removed from the freezer, sections underwent 3 consecutive five-minute 
washes with phosphate buffered saline, 0.2% Triton X (PBS-T). Subsequently, 
sections were incubated in blocking solution (3% donkey serum and 2% bovine serum 
albumin) for 30 minutes. Sections were then incubated with primary antibody in 
Immunobuffer I (2% Donkey serum in PBS-T) in the fridge overnight after 10 minutes 
on a rocker. 
• Day 2: After incubation with primary antibody sections underwent three rounds of five-
minute washes in PBS-T. From this point on the experiment was performed in 
darkness. After completion of washes, sections were incubated with secondary 
antibody in Immunobuffer I for 3 hours on a rocker at room temperature. Once 
incubated, sections were washed three times, each for five minutes, in phosphate 
buffer solution (pH of 7.4) and then incubated with 300 nM 4′,6-diamidino-2-
phenylindole (DAPI) solution for five minutes. Sections were then washed a further 
three, five-minute washes in PBS solution before being floated in phosphate buffer to 
enable mounting on uncoated microscope slides. Sections were then left to dry for a 
couple of minutes before fluorescent mounting media was added, and coverslip 
placed. These were then sealed with nail varnish and placed on paper towels and 
carefully placed in the fridge dry. 
Optimisation and antibody concentrations c-fos single stain:  
• Optimisation of c-fos antibodies: For c-fos cell staining, a dilution factor of 1:2000 of 
the ABE457 rabbit anti c-fos antibody was used. This was determined from a pilot study 
where three concentrations were used in different wells (Figure 15). The optimum 
concentration for the primary antibody was determined to be a 1:2000 dilution as the 
amount of c-fos staining was not increased at a concentration of 1:1000 whilst being 
absent at the lower concentration after a 1:5000 dilution. Additionally, background 






Figure 15. Optimisation of primary c-fos antibody (ABE457 rabbit anti c-fos). Images are 
of c-fos staining in rat prefrontal cortex in the prelimbic region, at x20 magnification. A) 1:1000 
dilution of ABE457 rabbit anti c-fos. B) 1:2000 dilution of ABE457 rabbit anti c-fos antibody. 
C) 1:5000 dilution of ABE457 rabbit anti c-fos. All images above had a secondary antibody 
(donkey anti-rabbit Alexa Fluor 488) concentration of 1:500. Scale bars = 100 µm. 
 
• Optimisation of secondary antibody (donkey anti-rabbit Alexa Fluor 488) concentration: 
Subsequently, a lower concentration of secondary antibody of 1:1000 dilution was 
found to be successful (Figure 16). Resulting in all subsequent experiments using this 
dilution factor as the same amount of fluorescent staining was found with reduced 
background fluorescence.  
 
Figure 16. Optimisation of concentration for the donkey anti-rabbit Alexa Fluor 488 








Antibody optimisation GAD67/c-fos stain: 
• The double staining protocol followed the same process as the single staining 
protocol. During double staining, the respective antibodies were simply mixed 
together and then applied to the sections. 
• Improved c-fos and GAD67 staining were achieved at dilutions of 1:1000 and 1:2500, 
respectively (Figure 17A & B) than at 1:2000 and 1:5000 (Figure 17D & E). Both 
secondary antibodies were applied at 1:1000. 
 
Figure 17. Optimisation of GAD67/c-fos double staining protocol. A) C-fos and B) GAD67 
and were found at dilutions of 1:1000 for the c-fos primary and 1:2500 for GAD67. D) C-fos 
and E) GAD67 were found at 1:2000 for the c-fos antibody and 1:5000 for the GAD67 antibody. 
Both DAPI stains C) & F) were achieved at 300nM, as per the manufacturer’s instructions. 
Secondary antibodies were applied at 1:1000. Scale bars = 100 µm. 
 
Image analysis:  
C-fos positive cell counting: C-fos count images were taken on the widefield 6 microscope, 
whereas GAD67 double staining photos were taken on a confocal microscope (University of 
Bristol Wolfson Bioimaging Facility). Pictures were taken at x10 magnification, with all settings 
consistent across all pictures. Photos were taken across 3 stereotaxic levels, on both left and 
right hemispheres, with an average being taken at the end. Position of images was kept 







Figure 18. Location of microscope images taken from tissue sections. This was across 





Cellular counts were then undertaken using FIJI (FIJI Is Just ImageJ) software, using the cell 
counter plugging. DAPI staining was then used to help cellular identification through the merge 
channels function. Occasional adjustment of brightness and contrast were used to aid the 
manual counting of cells.  
3.2.4 Statistical analysis 
 
The primary statistical test applied was a mixed model ANOVA, with Sidak corrected post hoc 
analysis. Sidak simple effects analysis was used for specific comparisons between PFC sub 
regions and treatments. 
3.3 Results 
3.3.1 Effect of ketamine and PCP on PFC c-fos expression 
 
Due to the number of slides lost (missing values shown in Table 3) from the first experiment 
no reliable statistical test could be applied and thus the data from this pilot are solely 
preliminary. Whilst marginal, our pilot suggested that 0.3 mg/kg PCP appears to increase c-
fos expression more than 1 mg/kg ketamine (Figure 19). The first c-fos staining experiment 
conducted, on which no statistics were performed, shows a numerical increase in mean c-fos 
count of the drug treated animals compared to vehicle control. At the IL, ketamine caused a 
23.30% increase in c-fos expression, whereas PCP caused a 71.66% increase. Increased c-
fos expression at the PL appeared more pronounced, with ketamine and PCP leading to a 
71.70% and 132.08% increase, respectively. Therefore, 0.3 mg/kg PCP potentially stimulates 
more c-fos expression at the IL and PL than 1 mg/kg ketamine. Due to number of missing 
values we undertook a repeat of this experiment. 
 
Table 3. Raw data from c-fos immunostaining pilot experiment. Due to issues with slide 
mounting many slides were unable to be photographed. Due to this we were unable to apply 
a reliable statistical test. 
 
 
JP4-1 JP4-2 JP4-3 JP4-4 JP4-5 JP4-6 JP4-7 JP4-8 JP4-9 JP4-10 JP4-11 JP4-12 JP4-13 JP4-14 JP4-15 JP4-16
lvl1-IL-L 72 114 0 75 21 52 52 131 64 77 51 72
lvl1-IL-R 83 137 0 145 34 0 127 95 114 96 57
lvl1-PL-L 73 103 0 111 38 49 62 237 67 117 57 98 78 93
lvl1-PL-R 75 127 0 147 46 181 78 116 70 126 96 91
lvl2-IL-L 98 121 199 69 85 44 38 104 75
lvl2-IL-R 93 116 227 93 129 36 93 69
lvl2-PL-L 145 100 235 126 23 101 122 33 64 111 80
lvl2-PL-R 134 88 214 113 8 145 47 65 65
lvl3-IL-L 129 60 147 88 31 65 57 113
lvl3-IL-R 131 144 54 8 59 57 51 132
lvl3-PL-L 90 129 183 67 0 88 108
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Figure 19. Pilot study for c-fos expression experiment. Expression was measured at the 
infralimbic (IL) and prelimbic (PL) cortices after i.p. administration of 1 mg/kg ketamine (n = 
6), 0.3 mg/kg PCP (n = 6) or saline control (n = 3) at 90 minutes before sacrifice. Data shown 
is average c-fos count ±SEM. 
 
The repeat of this experiment yielded a full and more reliable dataset. From this, a similar 
trend of a numerical increase in c-fos after treatment was observed (Table 4), although these 
were not significant, and therefore do not prove ketamine or PCP increased c-fos expression 
(Mixed Model ANOVA, F (2, 13) = 3.660, p = 0.055, Figure 20). There was therefore no 
interaction between drug and region (Mixed Model ANOVA, F (6, 39) = 1.688, p = 0.195, 
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Figure 20. Effect of 0.3 mg/kg PCP and 1 mg/kg ketamine on c-fos expression at the rat 
PFC. Expression was measured at infralimbic (IL), prelimbic (PL), cingulate (CG) and motor 
(Mt) regions of the prefrontal cortex after i.p. administration of 1 mg/kg ketamine (n = 6), 0.3 
mg/kg PCP (n = 6) or saline control (n = 4) at 90 minutes pre-termination. Data shown is 
average c-fos count ±SEM. 
 
However, there is an arguably marginal effect, and if repeated with a larger n number 
significance may be reached. Indeed, statistical power was limited by the uneven group 
number due to the smaller control vehicle group (n = 4). Although, both 1 mg/kg ketamine and 
0.3 mg/kg PCP lead to a numerical increase in c-fos expression at all four investigated regions.  
 
Table 4. Comparison of the effect of 1 mg/kg ketamine and 3 mg/kg PCP on c-fos 
expression. 
Comparison of effect of ketamine and PCP on PFC 
c-fos stimulation 
Region Comparison Mean 
difference 
Difference 
IL Ket vs Veh 22.917 64% 
PCP vs Veh 40.250 112% 
PCP vs Ket 17.333 29% 
PL Ket vs Veh 22.5 51% 
PCP vs Veh 37.0 84% 
PCP vs Ket 14.500 23% 
CG Ket vs Veh 13.167 69% 
PCP vs Veh 23.333 123% 
PCP vs Ket 10.167 31% 
Mt Ket vs Veh 2.917 146% 
PCP vs Veh 9.083 454% 
PCP vs Ket 6.167 123% 
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Out of the drug treatments, PCP appeared to stimulate more c-fos expression than ketamine 
as it caused a larger increase in mean c-fos expression across all regions, although this is a 
very preliminary result due to the lack of a main effect of treatment. Although, a significant 
difference when compared to vehicle was almost achieved (posthoc analysis, Sidak corrected, 
p = 0.053), more so than that of ketamine (posthoc analysis, SIDAK corrected, p = 0.394).  
A consistent finding across both c-fos staining experiments was a difference in regional c-fos 
expression, regardless of treatment. This result was highly significant in the complete c-fos 
run (Mixed model ANOVA, F (3, 39) = 71.714, p < 0.001, Figure 20). Sidak corrected posthoc 
analysis revealed that all regions significantly differed at a significance of p < 0.001 apart from 
IL and PL regions (Sidak corrected post-hoc analysis, p = 0.180). However, regional c-fos 
expression was not affected by any of the treatments, as shown by the lack of drug/region 
interaction (Mixed Model ANOVA, F (6, 39) = 1.688, p = 0.195, Figure 20). 
Although a significant increase in c-fos was achieved using separate independent samples t-
tests at the IL (p = 0.044), PL (p = 0.048) and CG (p = 0.023) whilst no significant increase 
was achieved at the Mt (p = 0.141). Although these separate t-tests should not be considered 
as a final analysis due to the lack of control over type I errors. 
3.3.2 Effect of different doses of ketamine on PFC c-fos expression 
 
Overall, results gained from the dose response experiment showed a large amount of variance 
(Figure 21) and no significant effect of ketamine dose was found (Mixed model ANOVA, F (3, 
8) = 1.073, p = 0.413). Whilst there appears to be a dose dependent increase in c-fos 
expression at the IL, PL and CG this should be interpreted with caution due to the large 
variance of the data, particularly that of the vehicle control and 1 mg/kg ketamine groups 
(Figure 21). Interestingly, an increase in c-fos expression at the Mt only seems to occur at the 
25 mg/kg ketamine dose, although a repeat experiment would be required to confirm this due 
to the lack of any robust and reliable effect. 
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Figure 21. Ketamine dose experiment on PFC c-fos expression. C-fos expression was 
investigated at the infralimbic (IL), prelimbic (PL), cingulate (CG) and motor (Mt) regions of the 
rat prefrontal cortex after i.p. injection of 1 mg/kg, 10 mg/kg and 25 mg/kg ketamine with saline 
control (n = 4). Data shown is average c-fos count ±SEM. 
 
Interestingly, there was an unforeseen effect of animal batch on c-fos expression which had a 
significant effect on c-fos expression between subjects (Mixed model ANOVA, F (1, 8) = 8.340, 
p = 0.020). There was also a significant interaction between batch and region (Mixed model 
ANOVA, F (3, 24) = 4.326, p = 0.014) and will have therefore influenced the c-fos experiment, 
and perhaps obscured an effect of ketamine dose. Simple effects analysis with SIDAK 
correction revealed a significant different between batches at the PL (mean difference 205.67 
c-fos per mm2, 95% CI 12.698 to 397, p = 0.039), CG (mean difference 281.992 c-fos per 
mm2, 95% CI 86.389 to 477.594, p = 0.010) and Mt (mean difference 228.283 c-fos per mm2, 
95% CI 62.094 to 394.472, p = 0.013) whilst almost reaching significance at the IL (mean 
difference 150.096 c-fos per mm2, 95% CI -15.817 to 316.009, p  = 0.070). This provided us 
with cause to investigate the influence of batch on our results. 
When separated by batch, the JB3 batch appear a clearer data set than that of the CH8 batch 
(Figure 22). The CH8 group displayed no main effect of dose between subjects (Mixed model 
ANOVA, F (3, 4) = 0.329), p = 0.806) whilst the JB3 batch did (Mixed model ANOVA, F (3, 4) 
= 10.100, P = 0.024). However, the small n number (n = 2) resulting from this batch separation 
reduces the reliability of this effect. Further, neither batch displayed any dose*region 
interaction (CH8 mixed model ANOVA, F (9, 12) = 1.648, p = 0.457 & JB3 mixed model 
ANOVA, F (9, 12) = 0.917, p = 0.599). 
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Figure 22. Ketamine dose experiment on PFC c-fos expression separated by batch. Data 
displayed for the infralimbic (IL), prelimbic (PL), cingulate (CG) and motor (Mt) regions of the 
rat pre-frontal cortex after i.p. injection of 1 mg/kg, 10 mg/kg and 25 mg/kg ketamine with 







Considering the significant effect of batch, we identified two individuals which displayed very 
high c-fos levels and thus causing a large amount of variance in their respective groups of 
vehicle and 1 mg/kg ketamine (Figure 22). It appears that these individuals, CH8-7 and CH8-
8, are possibly responsible for this difference in batch*region interaction as when they are 
excluded from the analysis the region*batch interaction is no longer significant (Mixed model 
ANOVA, F (3, 8) = 2.778, p  = 0.071). Indeed, when excluded from the overall analysis a clear 
effect of dose is observed between subjects (Mixed model ANOVA, F (3, 6) = 19.021, p = 
0.002) (Figure 23). There is also no dose*region interaction (Mixed model ANOVA, F (9, 18) 
= 1.715, p = 0.158), however, there is still a significant effect of batch (Mixed model ANOVA, 
F (1, 6) = 15.072, p = 0.008). Furthermore, the grounds to remove these two individuals is 
questionable. Indeed, although the counts of the PL and CG regions for CH8-7 approach a 
value of 2, overall the Z scores do not exceed 2 apart from the Mt count for CH8-8 (Table 5) 
and were therefore not officially counted as outliers. Thus, the data set with the excluded 
animals should be interpreted with caution. 
 
Table 5. Z-scores of CH8 7 & 8. 
Animal z-scores 
 IL PL CG Mt 
CH8-7 1.70 1.95 1.98 1.35 













































Figure 23. Ketamine dose experiment with CH8 – 7 (1 mg/kg) and CH8 – 8 (veh) removed. 
C-fos expression at the infralimbic (IL), prelimbic (PL), cingulate (CG) and motor (Mt) regions 
of the rat prefrontal cortex after i.p. injection of 1 mg/kg (n=3), 10 mg/kg (n=4) and 25 mg/kg 
(n=4) ketamine with saline control (n=3). Data shown is average c-fos count ±SEM. Mixed 
model ANOVA, Sidak corrected simple effects analysis, * = p<0.05, ** = p<0.01, *** = p<0.001.  
 
 
Sidak corrected post hoc analyses of the CH8-7 and CH8-8 removed dataset revealed 
significant differences between vehicle and the 10 mg/kg (p = 0.037) and 25 mg/kg (p = 0.002) 
doses and between the 1 mg/kg and 25 mg/kg doses (p = 0.004). Simple effects analysis 
revealed significant differences between doses in each region. In the IL, the significant 
difference was between 25 mg/kg and both the vehicle (mean difference 268.167 c-fos per 
mm2, 95% CI, 24.781 to 511.553, p = 0.032) or 1 mg/kg (mean difference 276.333 c-fos per 
mm2, 95% CI 32.947 to 519.719, p = 0.028) treatments. At the PL region, vehicle differed from 
the 10 mg/kg (mean difference 232.883 c-fos per mm2, 95% CI 29.752 to 436.014, p = 0.027) 
and 25 mg/kg (mean difference 316.375 c-fos per mm2, 95% CI 113.244 to 519.506, p = 0.006) 
treatments. There was also a significant difference between the 1 mg/kg and 25 mg/kg 
treatments (mean difference 249.958 c-fos per mm2, 95% CI 46.827 to 453.089, p = 0.019). 
At the CG region, vehicle differed from 10 mg/kg (mean difference 189.708 c-fos per mm2, 
95% CI 12.154 to 367.263, p = 0.037) and 25 mg/kg (mean difference 351.150 c-fos per mm2, 
95% CI 173.595 to 528.705, p = 0.002), 1 mg/kg differed from 25 mg/kg (mean difference 
228.833 c-fos per mm2, 95% CI 51.279 to 406.388, p = 0.015), and 10 mg/kg differed from 25 
mg/kg (mean difference 161.442 c-fos per mm2, 95% CI 2.632 to 320.252, p = 0.047). Finally, 
no significant differences were observed at the Mt, however significance was almost observed 
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between vehicle and the 25 mg/kg treatment (mean difference 210.375 c-fos per mm2, 95% 
CI -2.108 to 422.858, p = 0.052). 
3.3.3 GAD67 and c-fos colocalization 
 
Overall no significant effect of drug treatment was seen on either c-fos expression or c-
fos/GAD67 protein colocalization at the IL (Mixed model ANOVA, F (2, 13) = 0.173, p = 0.843, 
Figure 24) or PL (Mixed model ANOVA, F (2, 13) = 0.362, p = 703, Figure 24). There was a 
distinct difference in the populations of c-fos positive cells and the cells with colocalised c-
fos/GAD67 at both the IL (Mixed model ANOVA, F (1, 13) = 81.337, p<0.001) and the PL 
(Mixed model ANOVA, F (1, 13) = 85.323, p<0.001). Although none of the treatments exerted 
significant influence on this, as there was no significant interaction between treatment and 
colocalization at either the IL (Mixed model ANOVA, F (2, 13) = 0.181, p = 0.837) or PL (Mixed 




















































Figure 24. C-fos expression and c-fos/GAD67 colocalization at the infralimbic (A) and 
prelimbic (B) cortices after i.p. administration of 1 mg/kg ketamine (n=6), 0.3 mg/kg PCP 









3.4.1 Influence of 1 mg/kg ketamine and 0.3 mg/kg ketamine on PFC c-fos 
expression 
 
Overall, neither 0.3 mg/kg PCP or 1 mg/kg ketamine significantly increased c-fos expression. 
Whist it is well known that NMDAR antagonists increase PFC glutamate and activation 
(Homayoun and Moghaddam, 2007), we cannot confirm this at 1 mg/kg ketamine or 0.3 mg/kg 
PCP. However, whilst PFC stimulation is observed from ketamine in rats at doses between 10 
mg/kg (Littlewood et al., 2006) and 30 mg/kg (Kim et al., 2011), it is questionable whether 
these doses correspond with the 0.5 mg/kg infusion of ketamine used in humans. Our finding 
of a numerical increase in PFC c-fos expression after a 1 mg/kg dose, demonstrated to be 
effective in the ABT test (Stuart et al., 2015), may present evidence of a subtler excitatory 
effect, resembling more the 0.5 mg/kg infusion used in patients (Berman et al., 2000) and 
different from that observed at higher doses ranging between 10 and 25 mg/kg used in rats. 
Of course, interspecies extrapolation of pharmacological effects is difficult, especially in a 
pharmacokinetically sensitive response such as ketamine’s AD effect. To address this, Shaffer 
et al., 2014 applied a receptor occupancy (RO) normalization method using [3H]MK-801 
displacement studies combined with plasma concentration profiles of ketamine in rats after 10 
mg/kg. Through this model, they predicted that the receptor occupancy profiles between 0.5 
mg/kg infusion and 10 mg/kg s.c, are different on a temporal scale, with rat s.c reaching 65-
33% at 0.085-0.5 hours, in contrast to the human 0.5 mg/kg infusion reaching 31% at 40 
minutes. Interestingly, to mirror the RO profile, they predicted a 1.47 mg/kg infusion over 40 
minutes in rats would reproduce this pattern. Therefore, it is reasonable to posit that 1 mg/kg 
i.p. dose more closely resembles the 0.5 mg/kg infusion used in human studies, and that this 
could mediate the AD effects, although further testing would be required. 
Whilst no significant effect was discovered, PCP administration numerically increased c-fos 
expression at the IL, PL, CG and Mt more than ketamine (Table 4), on average of 30%. From 
this, we can speculate that 0.3 mg/kg PCP potentially elicited more PFC activation as 1 mg/kg 
ketamine or at least to a similar degree. As 0.3 mg/kg PCP has demonstrated no known AD 
effects and failed to induce positive bias in the JBT (Hales, Houghton and Robinson, 2017), 
whilst 1 mg/kg ketamine has induced positive bias in both the ABT and JBT (Stuart et al., 
2015; Hales, Houghton and Robinson, 2017), this could suggest that AD action is not solely 
NMDAR mediated. For example, ketamine’s action at the opioid system has been postulated 
to be essential for its antidepressant effect (Williams et al., 2018). Alternatively, the 
phamacodynamic differences between PCP and ketamine, such as NMDAR affinity, could be 
responsible for PCPs lack of AD efficacy.  
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However, NMDAR induced PFC stimulation has been strongly associated with ketamine’s AD 
efficacy (Li et al., 2016). Thus, it is unlikely that ketamine’s glutamate surge fails to play a role 
in its therapeutic mechanism. Instead, 1 mg/kg ketamine may exert an excitatory ‘sweet spot’, 
which lies under the excitatory threshold required for c-fos expression. Indeed, 1 mg/kg 
ketamine could elicit sufficient excitatory influence to cause AD effects with reduced 
psychotomimetic influence, whilst 0.3 mg/kg PCP may start to exceed this optimum excitatory 
window and begin to exert more dissociative side effects. This effect could be attributed to 
differences in ketamine’s and PCP’s KI values at the NMDAR, as PCP’s increased binding 
strength makes it the more potent drug (Lodge and Mercier, 2015). As PFC cortex stimulation 
is also associated with ketamine’s hallucinatory influence (Breier et al., 1997), the extent of 
excitation may be crux of distinguishing the two.  
It is also possible that ketamine’s unique pharmacology, including its action on the opioid 
system and subtle NMDAR induced stimulation at subanaesthetic doses, is responsible for its 
AD properties which other NMDAR antagonists such as PCP cannot recreate. As mentioned, 
PFC excitation and glutamate surge are associated with AD response, with ketamine’s 
dissociative effects displaying a positive correlation with AD efficacy (Luckenbaugh et al., 
2014). Interestingly, Williams et al., 2018 discovered that naltrexone, an opioid receptor 
antagonist, inhibited ketamine’s AD efficacy but without influencing its dissociative side 
effects. Therefore, it is possible that ketamine’s acute AD effect is mediated through the opioid 
system, whilst downstream effects resulting from NMDAR stimulation are necessary for 
downstream signalling resulting in longer lasting AD effects.  
This could explain the lack of acute effect of 0.3 mg/kg PCP in the JBT (Hales, Houghton and 
Robinson, 2017). However, further research would be required, as ketamine’s pharmacology 
extends to further transmitter systems such as the dopaminergic system. Additionally, it cannot 
be concluded that NMDAR receptor function is not required for ketamine’s short-term AD 
effects, as other NMDAR antagonists such as CP-101,606 display rapid AD action (Miller et 
al., 2014) but lack influence over the opioid system. Ultimately, the non-significant difference 
in PFC stimulation between 1 mg/kg ketamine and 0.3 mg/kg PCP suggests that ketamine’s 
specific pharmacodynamic effects, which may not be related to stimulatory influence, 
contributes to their difference in AD effects (Hales, Houghton and Robinson, 2017). However, 






3.4.2 Dose dependent effect of ketamine on c-fos expression 
 
The original dataset, shown in Figure 21, showed no statistical effect of dose. This was 
surprising as doses of 10 & 25 mg/kg have been demonstrated to stimulate c-fos expression 
(Duncan et al., 1998; Imre et al., 2006; Inta et al., 2009). After further investigation, an effect 
of batch was discovered which could have obscured the influence of increasing dose on c-fos 
expression. When analysed separately, an effect of dose was observed in the JB3 group and 
not found in CH8. This effect of batch may have been due to two individuals, CH8-7 & CH8-8, 
which displayed unusually high levels of basal c-fos expression despite being treated with just 
vehicle control or the 1 mg/kg dose. As both animals were housed together, this could have 
been a caged specific effect, as stress is known to induce c-fos expression (Piao et al., 2017). 
The exclusion of CH8-7 & CH8-8 results in a significant dose effect. However, the exclusion 
of these should be interpreted with care as there is no official basis on which to have the data 
removed. Furthermore, removal of these animals did not remove the significant effect of batch. 
With CH8-7 & 8 removed, increases in c-fos expression occur at the IL, PL and CG at 10 
mg/kg and 25 mg/kg. This corresponds with previous findings (Duncan et al., 1998; Imre et 
al., 2006; Inta et al., 2009). With this, c-fos expression at 25 mg/kg significantly differed from 
1 mg/kg at the IL, PL and CG. Differences between these doses gives cause to question AD 
effects observed at these doses with the FST (Yang et al., 2018) when 1 mg/kg achieves an 
AD effect in the ABT (Stuart et al., 2015) and JBT (Hales, Houghton and Robinson, 2017). 
It is possible that 1 mg/kg ketamine provides more subtle stimulatory effect than the higher 
doses of 10 mg/kg & 25 mg/kg. This subtle effect may be the key to ketamine’s AD efficacy, 
as higher doses of ketamine will begin to exert nonspecific effects. This relates to our previous 
notion of an excitatory ‘sweet spot’. Interestingly, Miyamoto et al., 2000 discovered that 
regional glucose uptake in the mouse brain was similar upon 30 mg/kg ketamine and 0.5 
mg/kg MK-801 administration. Therefore, it is possible that at these higher doses, ketamine’s 
neurobiological action begins to more closely resemble the action of its more potent NMDAR 
antagonist relatives. Thus, at these higher doses, ketamine’s NMDAR antagonism may inhibit 
its stimulatory influence and overshadow secondary pharmacological actions.  
Indeed, increased c-fos expression at the motor cortex at the 25 mg/kg dose, found in both 
the full data set (Figure 21) and data set with CH8-7 & 8 removed (Figure 23) was not 
significant but could suggest nonspecific locomotor effects of higher doses. This could suggest 
a dose dependent regional effect, in that higher ketamine doses of 25 mg/kg have less 
regionally specific stimulatory influence leading to motor side effects. Furthermore, whilst 
doses in the region of 10 mg/kg may lack influence over the Mt and more specifically target 
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more cognitive regions such as the IL and CG cortex, 8 mg/kg ketamine has still been reported 
to disrupt locomotion and cognitive function (Imre et al., 2006).  
Therefore, due to the subtlety of the influence of 1 mg/kg ketamine it is possible that, with our 
n numbers, c-fos staining is not sufficiently sensitive to detect this discrete effect, and that c-
fos expression may represent ketamine’s non-AD effects as the stimulation needed to induce 
significant expression is above the AD excitatory threshold. Thus, due to the small effect size 
a larger sample number would be required for future testing. From our CH8-7 & 8 removed 
data set, 10 mg/kg ketamine induces significant c-fos increase at the PL and CG cortex (Figure 
23). Considering that doses around 10 mg/kg cause behavioural alterations associated with 
dissociation (Imre et al., 2006), it is possible that this increase in c-fos is representative of 
ketamine’s dissociative actions. Furthermore, c-fos expression at regions such as the 
cingulate cortex resulting from ketamine have been linked to its dissociative effects (Nishizawa 
et al., 2000). Thus, at 10 mg/kg ketamine the excitatory AD threshold may have been 
exceeded. 
Thus, it is possible that increased c-fos expression in rats is representative of ketamine’s 
dissociative influence and not of its AD qualities. Indeed, 5 mg/kg ketamine has been shown 
to induce dissociative behaviours (Radford et al., 2017), although this was administered as an 
intravenous (i.v.) bolus which will produce more severe effects due the rapid delivery and 
assumedly higher brain concentration. Furthermore, as a dose of 3 mg/kg has shown to be 
ineffective in the FST (Chowdhury et al., 2017), despair based assays such as the FST may 
lack the sensitivity required to detect the AD effects of 1 mg/kg ketamine, which the ABT 
(Stuart et al., 2015) and JBT (Hales, Houghton and Robinson, 2017) achieved.  
3.4.3 Lack of effect of ketamine and PCP influence on c-fos/GAD67 
colocalisation 
 
To test whether any effect observed with ketamine or PCP was caused by the disinhibition of 
GABAergic interneurons, a popular notion behind the ketamine induced glutamate surge 
(Miller, Moran and Hall, 2016), we investigated whether any increased c-fos observed after 1 
mg/kg ketamine or 0.3 mg/kg PCP colocalized with GAD67. During this double staining 
experiment no effect of either 0.3 mg/kg PCP or 1 mg/kg ketamine on c-fos expression was 
observed (Figure 24). Additionally, little colocalization was observed and this was not affected 





The lack of findings here likely results from problems with staining. For example, when 
examined under the confocal microscope, a high level of autofluorescence was detected, and 
the signal from the primary antibody was dim. Thus, detection of c-fos expression and GAD67 
colocalisation was challenging. This could also explain the lack of replication of results found 
in the previous single stain run (Figure 20). Although, c-fos expression in GABAergic neurons 
has been previously identified using c-fos and GAD67 colocalisation in rats (Doron and 
Rosenblum, 2010; Hossaini et al., 2011) thus validating the experimental concept. However, 
this has not been performed specifically for GABAergic interneurons in the rat PFC. 
We expected to find a lack of c-fos/GAD67 c-fos colocalization due to the disinhibition 
hypothesis of ketamine’s action, which proposes subanaesthetic ketamine’s excitatory action 
lies with selective inhibition of GABAergic interneurons, facilitating increased PFC pyramidal 
neuron activity (Miller, Moran and Hall, 2016). Therefore, due to ketamine’s inhibitory action 
on GABAergic neurons, their activity and thus c-fos expression would be expected to be 
reduced.  
3.4.4 Limitations & considerations 
 
A caveat with the method of killing was the lack of perfusion. This may have obscured potential 
c-fos expressing neurons due to increased autofluorescence. Also, an inconsistency of 
different max values between experiments despite use of the same antibody was observed 
(Figure 25). A possible cause may be the age of the animals, with that of the PCP vs Ketamine 
experiment animals (Figure 25A) being older than those used in the ketamine dose experiment 
(Figure 25B). 
Another significant limitation was not using a rocker over the incubation with the primary 
antibody. This was an oversight of the researcher, who only applied this during incubation with 




Figure 25. Comparison of c-fos expression observed between the ketamine vs. PCP 
experiment and ketamine dose experiment. Images are representative of the IL cortex of a 
1 mg/kg ketamine treated animal from A) our PCP vs ketamine experiment and B) our 
ketamine dose experiment. Scale bars = 100 µm. 
 
Another important consideration is the administration route used and how this may have 
influenced our results. With a half-life 0.28h in the rat brain (Shaffer et al., 2014), ketamine is 
rapidly cleared. As it predominantly administered through an i.v. route, the drug is rapidly 
delivered. This leads to rapid increase and decline in plasma concentrations. Furthermore, 
whilst definite brain concentrations are unknown, this rapid plasma level elevation may be 
required for ketamine’s excitatory and therapeutic effect. As we applied an intraperitoneal 
injection, this slower delivery rate method would have resulted in a lower peak plasma 
concentration. Differences in administration route along with difficult dose estimations 
between rats and humans can also affect NMDAR occupancy making translation more 
challenging (Shaffer et al., 2014). 
Lastly, we consider the implications of c-fos as a neural marker. Whilst c-fos protein is a well-
established marker of neural activity, it is also a marker of stress and can even be induced 
with handling (Asanuma et al., 1992). This sensitive nature of induction can therefore confound 
subtle pharmacological influences. Furthermore, c-fos protein is not universally expressed 








Overall, the lack of a definite increase in PFC c-fos expression may suggest a subtle 
neurostimulatory effect lying under the c-fos expression inducing threshold. The numerical 
difference compared to PCP induced c-fos expression, which despite the use of a lower dose 
of 0.3 mg/kg appeared to exert more PFC stimulation than 1 mg/kg ketamine, may suggest 
that increased PFC stimulation is more associated with dissociative effects which PCP is more 
prone to induce. Alternatively, this may also rely on ketamine’s specific pharmacology, as the 
effect of 1 mg/kg ketamine on cognitive bias versus that of 0.3 mg/kg PCP (Hales, Houghton 
and Robinson, 2017), combined with our observation on non-statistically significant different 
effects on c-fos expression between the two treatments, could suggest this difference does 
not lie with stimulatory action. However, c-fos is likely not a sensitive enough measure to 
conclude this. 
1 mg/kg ketamine’s effect on c-fos expression also distinguishes it from 10 and 25 mg/kg 
doses. Our findings of increased c-fos expression at 25 mg/kg compared to 1 mg/kg, and a 
stimulatory effect of 10 mg/kg at the PL and CG cortex compared to control, differentiate 1 
mg/kg from these higher doses. As the literature supports the stimulatory influences of 10 & 
25 mg/kg (Duncan et al., 1998; Imre et al., 2006; Inta et al., 2009), it’s reasonable to conclude 
that whilst these doses meet the stimulatory calcium influx and thus neuronal stimulation 
threshold capable of inducing c-fos expression, 1 mg/kg ketamine does not. Therefore, the 
stronger excitatory influence of 10 & 25 mg/kg may be unnecessary for an AD effect which 
can be observed at 1 mg/kg (Stuart et al., 2015), and that these doses in fact differ more from 
the efficacious 0.5 mg/kg infusion used in humans than the 1 mg/kg dose in rats.  
In summary, c-fos is likely not sensitive enough to detect the subtlety of ketamine’s stimulatory 
influence or differential effects on GABAergic interneurons, resulting in non-statistically 
significant differences in 0.3 mg/kg PCP and our 1 mg/kg dose of ketamine. Future 
experiments could employ other methods of detecting neural activation and larger n numbers, 
to further characterize the neurobiological influence of 1 mg/kg ketamine. Despite this, our 
results lend support to the difference influence seen between 1 mg/kg and 10 and 25 mg/kg 









































Given the influence of 1 mg/kg ketamine on affective bias (Stuart et al. 2015) and having 
demonstrated a lack of influence over reward-induced positive bias (unpublished), ketamine’s 
influence appears to have a specific cognitive effect. For validation, we pursued ketamine’s 
influence using another memory processing task. This would determine whether the effect 
observed is specific to affective bias, or whether non-specific effects such as memory 
disruption are confounding results from the affective bias task. 
Acting as an NMDAR antagonist ketamine is liable to cause memory disruption due to the 
NMDARs role in memory formation. This consists of a ‘coincidence detector’, whereby the 
properties of the NMDAR allow it to trigger LTP, which occurs when membrane depolarisation 
removes Mg2+ block and glutamate binds to and opens the NMDAR channel. NMDAR 
activation then strengthens the synaptic connection through synaptic modifications such as 
increased AMPAR expression (Bliss and Collingridge, 1993). Thus, the NMDARs role in LTP, 
and evidence of ketamine’s short term memory impairing influence (Adler et al., 1998) 
warrants investigation of ketamine’s potential memory disruption in the ABT. 
Whilst the effect of NMDAR antagonists on recognition memory is well documented, the 
effects of the lower doses of ketamine on memory have received less attention. In rats, 
investigation of subanaesthetic doses typically ranges from 15 – 30 mg/kg (Imre et al., 2006; 
Moosavi et al., 2012; Wesierska, Maciasgonzalez and Bures, 1990). However, evidence of 
1mg/kg ketamine induced memory impairment in the object recognition test at 20 minutes pre-
treatment (Pitsikas, Boultadakis and Sakellaridis, 2008) suggests the 1 mg/kg dose in the ABT 
could lead to memory impairment. However, Stuart et al. 2015 administered ketamine 1 hour 
before treatment.  
We thus aimed to elucidate a difference between 20 minute and 1-hour pre-treatment times, 
at the doses of 10 mg/kg and 1 mg/kg using the object in place task (OIP). This would allow 
us to determine the importance of dose and pre-treatment time for the memory disruptive 
effect of ketamine in rats, and thus uncover whether this could have confounded the results 
from Stuart et al. 2015. We focused on ketamine’s effects on memory acquisition which is 
more sensitive to NMDAR blockade suggesting more NMDAR dependence (Barker and 









12 male lister hooded rats were used to conduct the object in place task (~300–350 g, Harlan, 
UK), the same strain used to undertake the affective bias test by Stuart et al. 2015. Animals 
were housed in pairs and all experimental work was conducted within a 12:12 h light–dark 
cycle (lights off at 0700h) between 9 am – 5pm. All animals had ad libitum access to laboratory 
chow and water and were provided with environmental enrichment (cardboard tube, plastic 
housing and chew block). Weight of the animals was monitored weekly. 
All work was approved by the UK Home Office and was conducted in adherence to the 
regulations of the 1986 Animals (Scientific Procedures) Act.  
4.2.2 Drug treatment 
 
Each ketamine treatment was made with sterile 0.9% saline solution using a dose volume of 
1 ml/kg. Ketamine used was purchased from Sigma Aldrich. Treatments were administered 
through i.p. injection either 20 minutes or 1 hour before memory acquisition stage. 
4.2.3 Object in place task 
 
Experimental set up 
The experiment took place in a wooden arena (90x100 cm) with walls of 50 cm in height and 
no top. The left side wall was painted grey to provide the rats with orientation. The side to the 
experimenter was covered by a black curtain 1.5 m in height keeping them out of sight during 
the task. The floor of the arena was covered in saw dust. The objects used were constructed 
from Duplo and were different in size, colour and shape between each experiment. As the 
experiment progressed, the objects became more elaborate to retain the animal’s interest. 
The position of objects was counterbalanced along with the pair that was swapped and object 
colour was randomized throughout the experiment. Video recordings of the rats was taken 
through a web cam which was positioned 1.5 m above the arena and inverted so that the 
arena was in full view. 
Behaviour testing 
Firstly, animals were handled for a week and subsequently habituated in the arena with no 
objects present for 4 days for 10-15 minutes each. Once habituated, the experiment consisted 
of a 5-minute sample phase followed by a 1-hour delay and a subsequent final 3-minute test 
phase for each animal. During the sample phase, the rat was placed in the centre of the arena 
facing forward and was left to encounter the 4 objects. Once the sample phase was complete, 
the rat was removed and returned to its cage. Following a one-hour delay, the rat was again 
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placed in the arena to begin the test phase. At the test phase, the position of either the 2 left 
or 2 right objects had swapped positions with each other. After each exposure the objects 
were wiped down with ethanol and saw dust removed to avoid the influence of any olfactory 
cues. Recognition memory was then assessed by measuring the exploration of each object 
pair. If OIP memory is intact the moved pair will receive more interest. 
Due to the length of the delay, the experiment was undertaken with a staggered design. The 
schedule for the sample/test phases was kept consistent throughout the experiment, and the 
pre-treatments were scheduled around it. 
4.2.4 Statistical analysis 
 
Pilot: One sample t-test. 




To determine if the animals could perform the task a pilot study free of any treatment was 
conducted. Here the animals demonstrated significantly more interest in the moved objects 
(One sample students t-test: t = 4.141, p = 0.002, n = 12, Figure 26). We therefore established 






















Figure 26. Pilot experiment for the object in place task. Data shown as mean±SEM, n = 






Overall, we observed a significant effect of dose (Two-way repeated measures ANOVA, F (2, 
22) = 5.678, p = 0.010). However, there was no overall effect of pre-treatment time (Two-way 
repeated measures ANOVA, F (1, 11) = 0.921, p = 0.358) and no interaction between time 
and dose (Two-way repeated measures ANOVA, F (2, 22) = 2.794, p = 0.083). Simple effects 
analysis with Sidak correction revealed that the significant effect of dose occurs within the 20-
minute pre-treatment group, specifically between the vehicle and 10 mg/kg treatment (mean 
difference, 0.294, with 95% CI 0.017 to 0.571, p = 0.037). Simple effects analysis also revealed 
that a statistically significant difference was almost achieved between vehicle and 1 mg/kg, 
within the 20-minute pre-treatment group (mean difference, 0.324, with 95% CI -0.020 to 
0.668, p = 0.066). Furthermore, no significant effect of dose was observed at the 1-hour pre-
treatment, despite evident numerical difference between the 10 mg/kg dose compared to both 
the vehicle and 1 mg/kg treatment. 
 



























Figure 27. Effect of ketamine dose and pre-treatment time on the test phase of the OIP 
task. Data shown as mean±SEM, Trial 1 n = 12. Two-way repeated measures ANOVA, Sidak 
corrected simple effects analysis, * = p<0.05, ** = p<0.01, *** = p<0.001.  
 
Sidak corrected simple effects analysis was also applied to assess the effect of pre-treatment 
at each dose. Differences between pre-treatment times at both vehicle (mean difference 
0.072, with 95% CI -0.155 – 0.298, p = 0.501) and 10 mg/kg (mean difference 0.022, with 95% 
CI -0.200 – 0.244, p = 0.832) were not significant. However, the difference between pre-
treatment time at 1 mg/kg was close to achieving significance (mean difference 0.252, with 




With the object in place task requiring a sample phase for the acquisition of the objects and 
their location there is the opportunity to induce an object bias, that is a particular object pair is 
found more interesting than the other. To prevent this, counterbalance measures of both object 
position and colour were taken. To confirm the effectiveness of our counterbalance measures 
the sample phase data was analysed.  No significant effect of dose (Two-way repeated 
measures ANOVA, F (2, 22) = 0.106, p = 0.900) or pre-treatment time (Two-way repeated 
measures ANOVA, F (1, 11) = 0.132, p = 0.723) was found. Thus, object bias was not an 
influence on any effect observed.  






































4.4.1 10 mg/kg ketamine impairs OIP memory  
 
Our finding of the memory impairing effect of 10 mg/kg demonstrates this dose, widely used 
in the FST, exerts cognitive deficits which could confound AD effects. However, this effect only 
reached statistical significance at the 20-minute pre-treatment time (Figure 27). Despite this, 
numerically, there is evidence of OIP memory attenuation at 10 mg/kg at the 1-hour pre-
treatment time, as the animals show a lack of discrimination between the novel and sample 
object orientations (Figure 27). Although, a lack of statistical support does not allow a reliable 
conclusion. However, as object in place memory acquisition is dependent on NMDAR 
transmission (Barker and Warburton, 2015), memory disruption at the 1-hour pre-treatment is 
probable.  
Support for a memory impairing effect of 10 mg/kg is provided by the current literature. For 
example, 15 mg/kg i.p, ketamine at 40 minutes prior training increases escape latency of the 
Morris water maze (Moosavi et al., 2012) whilst Alessandri, Bättig and Welzl, 1989 
demonstrated that at 20 minutes 12.5 mg/kg ketamine impairs water maze performance. 
Further, Chrobak, Hinman and Sabolek, 2008 demonstrated at 20-minute pre-treatment both 
12.5 and 2.5 mg/kg impaired acquisition of the radial water maze task in rats. Thus, 
considering the previous works, 10 mg/kg ketamine is likely to impair OIP performance, 
demonstrating its unsuitability for studying specific cognitive processes such as the ABT.  
4.4.2 Effect of pre-treatment time on 1 mg/kg ketamine induced memory 
impairment  
 
Our findings at 1 mg/kg at 1-hour pre-treatment time support the validity of the results from 
Stuart et al., 2015 as there was no evidence of memory impairment. At 20 minutes pre-
treatment on the other hand, 1 mg/kg appears to have attenuated recognition memory. 
However, whilst there is a clear numerical difference between the discrimination index seen 
at the 20 minute and 1-hour pre-treatment with 1 mg/kg compared to vehicle treat groups, a 
statistically significant effect was not found. These results must therefore be interpreted with 
caution.  
Considering ketamine’s pharmacokinetic properties discussed in the previous section, 1-hour 
would theoretically provide enough time for sufficient plasma clearance and recovery from its 
cognitive impairing effect. Indeed, as demonstrated by Parwani et al., 2005, ketamine’s effect 
on memory is correlated with its plasma concentration and does not lead to lasting long-lasting 
effects. Furthermore, ketamine’s memory impairing effect is transient and not present the next 
day despite repeated administrations in humans (Zhou et al., 2018). Therefore, it is reasonable 
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to conclude that at subanaesthetic doses ketamine only impairs memory at a time of sufficient 
plasma concentration.  
Consistent with this the animals tested here appeared to retain the ability to form OIP memory 
at 1 mg/kg at 1-hour pre-treatment. Thus, the animals receiving the dose and pre-treatment 
time used in Stuart et al., 2015 would be free of memory impairment at the time of testing. 
This verifies that their results are due to the influence of affective bias, and not a memory 
impairment effect that simply disrupts the association between the digging substrate and 
affective state manipulation. Furthermore, the potential difference in OIP memory at the 1-
hour and 20-minute time point suggests that the threshold for ketamine’s affective bias specific 
effect is easily exceeded due to the fact that ketamine plasma levels at 20 minutes compared 
to 1-hour post treatment could be enough to cross it. 
4.4.3 Conclusions 
 
Our findings suggest that doses of 10 mg/kg, given 1-hour prior testing will exert memory 
impairing effects. This could affect behaviour when assessing of AD efficacy. Alternatively, 1 
mg/kg at 1-hour pre-treatment appeared free of this memory disturbance. Whilst not 
statistically significant, the doses used in ABT/JBT (Stuart et al., 2015; Hales, Houghton and 
Robinson, 2017) is supported by the numerical similarity between 1 mg/kg at 1 hour and 
vehicle control. Thus, we conclude the effect observed by Stuart et al. 2015 was specific to 
affective bias, and not the result of memory impairment. 
We also demonstrated how 10 mg/kg ketamine exerts longer lasting effects to 1 mg/kg. Whilst 
there was evidence of a lack of memory impairment with 1 mg/kg at 1 hour, 10 mg/kg exerted 
robust memory disturbance at both pre-treatment times. This suggests that 10 mg/kg exerts 
longer lasting nonspecific effects including memory impairment and dissociation, likely due to 
increased plasma presence. This could confound ketamine’s antidepressant action in rats.  
Furthermore, 1 mg/kg could elicit mild disruption of the relevant networks due to its mild 
stimulatory effect on the PFC, with reduced nonspecific effects. This may more closely 
resemble the 0.5 mg/kg infusion given to human subjects (Berman et al., 2000) than does the 
more disruptive 10 mg/kg. Thus, further application of 1 mg/kg ketamine in rats is warranted 








































The principal aim of this project was to investigate the AD action of 1 mg/kg ketamine in rats 
to improve our understanding of its AD mechanism. Through differentiating the effects of 1 
mg/kg with higher commonly used doses of 10-25 mg/kg in rats, and against the non-AD 
NMDAR antagonist PCP we aimed to uncover information on ketamine’s AD mechanism. 
Additionally, we explored a novel method of assessing pharmacological affect bias 
manipulation. This would offer a valuable research tool for ketamine’s preclinical research and 
support work by Stuart et al., 2015. 
We first endeavoured to assess the reproducibility of the ABT used to discover 1 mg/kg 
ketamine’s ameliorating effect on previously acquired negative biases (Stuart et al., 2015). 
Failure to replicate results achieved by Hinchcliffe et al., 2017 through the lack of a 2 vs 1 
positive bias or cortisol induced negative bias lead us to explore a modified version of the bowl 
digging ABT using flavoured solutions instead of digging substrates. Application of this 
modified methodology resulted in successful induction of a positive reward induced bias. From 
this, we attributed previous difficulties encountered in the bowl digging ABT to the extensive 
animal interaction required due to the practical aspect of the test which provided opportunity 
to compromise affective bias induction. Thus, future researchers applying these techniques 
should remain as objective as possible during these experiments. Additionally, successful 
induction of a positive bias through a distinct methodical approach supports the validity of the 
ABT, and thus its application to investigate ketamine’s effect on affective bias. 
An argument against ketamine’s ameliorating effect on cognitive bias is that this may be the 
result of amnesia, which would disrupt the animals’ associative memory. We therefore applied 
the object in place task to investigate whether the dose and pre-treatment time used by Stuart 
et al., 2015 causes memory impairment. We found that the widely applied 10 mg/kg dose 
induced disruption of OIP memory. This was only significant at the 20-minute pre-treatment 
time but the lack of OIP discrimination formed at the 1-hour treatment suggests a memory 
impairment effect. At the 1 mg/kg dose, a potential effect of time was observed. Whilst lacking 
statistical backing, OIP memory at the 1-hour pre-treatment time appeared to be intact, which 
was not observed with the 20-minute pre-treatment. This suggests that the dose and pre-
treatment time used in the ABT study by Stuart et al., 2015 (1 mg/kg at 1 hour) does not 
influence memory and that there finding was representative of an effect on affective bias and 
not general memory impairment. 
Another motive behind the application of the OIP test was the involvement of glutamatergic 
circuitries involving the PFC and Perirhinal cortex required in functional OIP memory (Barker 
and Warburton, 2008). As discussed, the PFC is heavily involved in depression and likely to 
be a principal region involved in ketamine’s therapeutic effect. Therefore, application of the 
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OIP task provides scope to further elucidate ketamine’s effect on PFC neurobiology. To this 
end, 10 mg/kg appears to exert a disruptive effect on this circuit, whilst 1 mg/kg at on hour 
may exert reduced if any disruption. Therefore, 1 mg/kg ketamine at one hour retains its 
specific influence whilst doses of 10 mg/kg exceed it and could lead to increased disturbance 
of the networks involved in ketamine’s AD mechanism. 
To characterize ketamine’s effect on PFC cortex activation, we investigated changes in c-fos 
expression after ketamine treatment and how this compared to a low dose of 0.3 mg/kg PCP, 
a structural analogue of ketamine. Overall, our results did not provide a definitive conclusion 
on whether 1 mg/kg led to c-fos stimulation. In the first experiment, consisting of the 
comparison between ketamine and PCP, a numerical increase in c-fos expression was noted 
from ketamine and PCP. Speculatively, this could suggest a mild stimulatory effect of ketamine 
at 1 mg/kg, sufficient to produce an AD effect (Stuart et al., 2015) and perhaps cause reduced 
memory impairing effects (Figure 27). Moreover, the larger stimulatory influence of PCP (Table 
4) may represent a larger induced glutamate surge, likely resulting from its stronger NMDAR 
block and distinct pharmacodynamic properties. Additionally, 1 mg/kg ketamine’s and 0.3 
mg/kg PCPs distinct influence on cognitive bias, with ketamine successfully inducing a positive 
bias (Hales, Houghton and Robinson, 2017), despite no significant differences in PFC c-fos 
stimulation (Figure 20) could suggest secondary pharmacological actions are also responsible 
for ketamine’s AD effect. 
However, when investigating the effect of ketamine dose on c-fos expression, and c-fos/GAD-
67 colocalization, a numerical increase in c-fos expression was not found at 1 mg/kg. This 
negative finding may suggest that 1 mg/kg ketamine elicits a subtle excitatory influence which 
fails to reach the threshold required for increasing c-fos expression, or that 1 mg/kg does not 
exert a stimulatory effect. Alternatively, c-fos expression and AD efficacy may be induced by 
independent mechanisms. Considering the evidence of 1 mg/kg ketamine possessing AD 
activity (Stuart et al., 2015), and that this dose lacked a definite effect on c-fos expression the 
frequent use 10-25 mg/kg in rodent AD research (Zanos et al., 2016; Yang et al., 2018) should 
be interpreted with caution as secondary effects will increase at higher doses. Thus, it may be 
possible that increased c-fos expression observed at 10 and 25 mg/kg (Duncan et al., 1998; 
Imre et al., 2006; Inta et al., 2009) is actually representative of more general effects, not 
specific to the affective bias pathway which is only achieved at lower doses of 1 mg/kg (Stuart 
et al., 2015). This could be the crux of ketamine’s AD pharmacology, in that higher doses, or 
other NMDAR antagonist lack 1 mg/kg ketamine’s specific action at the PFC. Indeed, this 
threshold could lie within a thin margin which is difficult to replicate with other treatments as 
demonstrated by the difference we observed between a 20 minute and 1-hour pre-treatment 
time of 1 mg/kg on OIP memory (Figure 27). 
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The significance of dose in ketamine’s AD action likely implicates its temporal pharmacokinetic 
properties. Having rapid pharmacokinetics, a brief plasma presence may be required for a 
transient glutamate surge critical for ketamine’s AD effect. Thus, anything above this threshold 
may result in secondary and non-AD actions such as dissociative symptoms or memory 
impairment. Considering that our data show that OIP memory is intact at the AD dose of 1 
mg/kg, but disrupted at 10 mg (Figure 27), it is possible that the more intense glutamate surges 
induced by higher dosage is unnecessary to elicit an AD effect. This difference in stimulatory 
effect is also demonstrated by the different c-fos expression observed at 1 & 10 mg/kg. Thus, 
to achieve and AD effect as seen by Stuart et al., 2015 at 1 mg/kg, the level of stimulation 
seen at 10 mg/kg is excessive and could even occlude AD effects through increased 
nonspecific actions such as memory impairment.  
Of course, when discussing dissimilitude between doses, and especially between species, the 
method of delivery is crucial. Therefore, the limitations of the compatibility of i.p. dosing in rats 
versus the 0.5 mg/kg infusion of ketamine in humans (Berman et al., 2000) must be 
considered. As posited by Shaffer et al., 2014 through their receptor occupancy model, 10 
mg/kg i.p. injection is likely to result in different NMDAR occupancy than 0.5 mg/kg infusion. 
They posit that a 1.47 mg/kg infusion over 40 minutes in rats would most closely match the 
NMDAR occupancy profile of 0.5 mg/kg 40-minute infusion in humans. Therefore, it is possible 
that a 1 mg/kg i.p. dose in rodents results in NMDAR binding more similar to the human 40-
minute infusion than the more commonly used doses of 10 and 25 mg/kg. Similar to the 
transient dissociative symptoms experienced during ketamine’s clinical trial (Berman et al., 
2000), 1 mg/kg ketamine led to brief memory impairments in the OIP task assessed at 20 
minutes which appeared to resolve after 1 hour (Figure 27). In contrast, 10 mg/kg disrupted 
OIP performance at both time points, resembling higher clinical doses leading to more 
cognitive disruption (Adler et al., 1998). 
Despite difficulties in interspecies extrapolation, we can be confident that a transient 
pharmacodynamic influence results in ketamine’s lasting AD effects. This may be 
compromised at higher doses due to longer lived drug effects. When administered to rats, 
[3H]MK-801 binding has been shown to be inhibited by 3 mg/kg (i.v.) ketamine in a time 
dependent manner, with [3H]MK-801 receptor occupancy inhibition decreasing from 67% to 
19% in 20 minutes (Fernandes et al., 2015), demonstrating ketamine’s brief action at the 
NMDAR. As a transient glutamate surge is associated with ketamine’s AD effect (Milak et al., 
2016), higher doses may lead to increased secondary effects due to a prolonged glutamate 
surge. As NMDAR receptor occupancy is closely related to ketamine plasma concentration 
(Fernandes et al., 2015), the increased clearance time necessary for higher ketamine doses 
will prolong any pharmacodynamic effect. 
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Evidence of prolonged glutamate increase by increasing ketamine dose is provided by 
Moghaddam et al., 1997, who found a significant increase in extracellular PFC glutamate with 
i.p. 20 and 30 mg/kg at 80 minutes post injection, whilst 10 mg/kg only retained significance 
until 60 minutes post injection. The longer duration of this glutamate surge corresponds with 
the disrupted OIP performance observed at 10 mg/kg at 1 hour, and the potential increase in 
c-fos expression at 25 mg/kg. This could be representative of a prolonged glutamate surge 
accentuating psychotomimetic effects and memory impairment whilst reducing the specific 
targeting of the affective bias pathways.  
Regional specificity may also be behind the difference between the AD efficacy of 
subanaesthetic doses. This regional specificity may arise due to different receptor densities. 
For example, Li et al., 2017 found increased glutamate at the perigenual anterior cingulate 
cortex (pgACC) compared to the anterior midcingulate cortex (aMCC) and proposed this was 
due to AMPAR/NMDAR ratios. Low doses of ketamine may therefore possess increased 
therapeutic efficacy due to their ability to specifically target regions compared to more global 
inhibition elicited by higher doses. It may be that differences in NMDAR/AMPAR ratios 
facilitate targeting of specific subnetworks including regions such as the ACC. Our finding of 
a numerical increase in c-fos expression at the motor cortex at 25 mg/kg (Figure 21), a region 
not involved in ketamine’s AD effect, supports this. This might also help explain the necessity 
of the AMPAR in ketamine’s AD mechanism (Maeng et al., 2008), as it may be that increased 
AMPAR receptor presence facilitates increased NMDAR channel opening, resulting in 
increased susceptibility to inhibition through ketamine’s uncompetitive mechanism. This may 
be increasingly relevant for depressed patients due to differences in cerebral 
glutamine/glutamate levels (Yüksel and Öngür, 2010) and potential NMDAR/AMPAR 
expression (Treccani et al., 2016). 
Specific targeting of these regions may then result in correcting network dysfunction, 
amending abnormalities in core networks implicated in depression such as the DMN (Walter, 
Li and Demenescu, 2014). This acute effect of normalising abnormal connectivity (Walter, Li 
and Demenescu, 2014) could then also facilitate neuronal plasticity and the relearning of 
positive social behaviours associated with remission (Harmer, Goodwin and Cowen, 2009). 
This may first manifest as a change in cognitive bias, which facilitates remission through 
removing negative self-rumination and negative interpretation of information as proposed by 
the cognitive neuropsychological hypothesis of depression (Harmer, Goodwin and Cowen, 
2009). Thus, this could explain the importance of the specific influence on affective bias 
observed at 1 mg/kg (Stuart et al., 2015). 
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Whilst previous studies have researched ketamine’s influence on cognitive bias their 
neurobiological observations are principally derived from neuroimaging studies such as MRI 
(Murrough et al., 2015; Reed et al., 2018). Whilst these provide parameters such as glucose 
metabolism or blood oxygenation, they fail to provide more intimate and direct variables. For 
this reason, the application of animal research in depression is essential, so that specific drug 
targets are identified.  
The study of pharmacological influences on cognitive bias in rodents using the ABT remains 
a novel and reliable approach to investigate the AD mechanism of ketamine. The fact that we 
were able to identify the reason for the failure of the task in this current work supports the 
validity of this test and demonstrates its sensitivity. Furthermore, the positive bias induced in 
the modified flavour preference ABT provides further support towards the research on affective 
bias in rodents. Thus, our conclusions provide guidance for future researchers undertaking 
this test who must be aware of the importance of objectivity when undertaking the ABT. We 
also provided validation for a less labour-intensive alternative. 
In order to fully elucidate ketamine’s AD mechanism, it is essential to continue this line of 
research. Through it there is opportunity to dissect how ketamine effects cognitive bias at a 
basic level, which will ultimately allow design of new antidepressant treatments. Due to the 
potential importance of the affective bias influence in ketamine’s AD effect, investigating this 
could result in a furthered understanding of its mechanism at both a cognitive and molecular 
level. Therefore, the importance of 1 mg/kg ketamine’s neurobiological influences and their 
role in affective bias should be further characterised. For example, the importance of  
subanaesthetic ketamine’s glutamate surge, which is associated with its AD action (Abdallah 
et al., 2017a), should be investigated in the JBT and ABT. As we differentiated 1 mg/kg from 
higher doses of 10 and 25 mg/kg, it would be interesting to determine whether 1 mg/kg is 
sufficient to cause a glutamate surge in the rat PFC, and whether disruption of this would 
influence ketamine’s efficacy in the JBT or ABT (Stuart et al., 2015; Hales, Houghton and 
Robinson, 2017). This information could determine the importance of ketamine’s stimulatory 
effect and whether it is required for the cognitive effects observed at 1 mg/kg in rats, and 
whether these are associated with a glutamate surge. 
The role of ketamine’s secondary pharmacological actions at 1 mg/kg in its cognitive influence 
observed in ABT and JBT should also be investigated. Due to the possible subtlety of 
ketamine’s stimulatory influence at the PFC at 1 mg/kg, observed from a lack of significant 
effect on c-fos expression, and its potential similarity in its effects on c-fos expression as PCP 
(Figure 20), it is possible that ketamine’s secondary pharmacological actions contribute to its 
AD effect. Indeed, as mentioned, naltrexone has shown to reduce ketamine’s AD effects 
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(Williams et al., 2018). Therefore, it is worth exploring the influence of, for example, opioid 
receptor antagonists on ketamine’s neurobiological effects at 1 mg/kg in rats. This could 
involve in vivo electrophysiology readings at the PFC and fMRI. This could then be applied to 
results found from investigating how opioid receptor antagonism influences ketamine’s effect 
on the JBT and ABT. From this, a further understanding of ketamine’s AD action could be 
gained. 
We conclude that dose plays a vital role in ketamine’s AD mechanism, as it allows more 
specific and less disruptive action at relevant regions such as the mPFC. This potentially 
allows a subtler stimulatory influence facilitating AD action and reduced psychotomimetic side 
effects, as well as facilitating a more specific pharmacodynamic influence. Thus, the low dose 
of 1 mg/kg allows specific targeting of neural circuits leading to efficacy in the ABT (Stuart et 
al., 2015) and JBT (Hales, Houghton and Robinson, 2017) and reduced nonspecific secondary 
actions such as memory impairment. However, limitations of our research including lack of 
significance and small n numbers warrants further research of 1 mg/kg ketamine. Furthermore, 
in order to gain the intimate knowledge required for designing new AD treatments, animal 
research using cognitive focused assays such as the ABT must be applied as they test a real 
depressive trait and go beyond a simple screening test. Through this, our understanding of 
depression will progress, and the discovery of effective new treatments free of ketamine’s side 
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